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Abstract
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder which
is characterized by motor and non-motor disorders. The prevalence of PD is high among elderly
patients. Due to the chronic nature of PD, increasing prevalence and ageing population, it is
important to understand the burden of PD at various stages of patient’s life so that value of PD
therapies can be assessed. While direct healthcare costs during the life time of PD were assessed
in previous studies, there is lack of information about end of life costs in PD patients. This
dissertation aimed at filling the gap in literature by assessing end of life (EOL) costs in PD
patients.
First, the duration of EOL period in PD patients was identified through a data-driven
approach using Joinpoint regression (piece-wise linear regression). We determined the EOL
period in PD patients to be the 9-mon period prior to death. Second, we assessed the direct
healthcare cost burden of PD patients during the 9-mon EOL period. Further, a cohort of non-PD
patients with comparable demographics and baseline comorbidity burden was identified. Based
on the results from generalized linear models, we found that EOL costs were significantly higher
in PD patients when compared to non-PD patients. Last, we assessed the EOL costs among
patients who died at hospice facilities and non-hospice facilities. In order to compare EOL costs
among patients who died at hospice facilities and non-hospice facilities, we used ordinary least
squares (OLS) regression and an instrumental variable regression in order to minimize the bias
due to lack of randomization. While results from OLS regression indicated that patients in
hospice cohort had significantly higher costs when compared to non-hospice cohort, results from
ii

IV regression indicated that costs are not significantly different in both the cohorts. Overall, our
study helps understand the EOL cost burden of PD patients enrolled in Medicare so that
treatment priorities can be set and value of PD therapies can be assessed.
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CHAPTER 1
INTRODUCTION
Parkinson’s disease
Overview of Parkinson’s disease
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder which
affects a person’s ability to control their movements, body and emotions. It belongs to a group of
conditions which are referred to as motor system disorders. Although the exact cause of PD is
unknown it is attributed to the loss of neurons in the substantia nigra region of brain which leads
to reduced dopamine production (Samii, Nutt, & Ransom). PD is also characterized by the
accumulation of a protein, alpha-synuclein, also called Lewy Bodies in the brain stem, spinal cord
and cortical regions (Lees, Hardy, & Revesz). Genetic mutations are likely to account for 10% of
the cases while the majority (90%) of the cases are considered sporadic (De Lau & Breteler, 2006).
The primary motor symptoms of PD include tremor, bradykinesia, rigidity and postural instability.
Depression, apathy, sleep disorders and erectile dysfunction are some of the non-motor symptoms
of PD (Chaudhuri & Schapira, 2009; Jankovic, 2008). The course of PD usually starts with a
diagnosis and a maintenance phase where complete symptom relief can be achieved with
pharmacological treatment. It is followed by a complex phase where motor complications and
neuropsychiatric complications occur. The disease course ends with a palliative phase where
advanced PD is treated followed by the end of life care (Clarke, Sullivan, & Mason, 2006; Lokk
& Delbari, 2012).
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Diagnosis
Currently, there are no reliable diagnostic tests or markers to diagnose PD. Hence,
physicians rely on the presence of cardinal symptoms which include tremor, bradykinesia, rigidity
and asymmetric onset for the clinical diagnosis of PD (Jankovic, 2008). Although functional
neuroimaging techniques such as single photon emission CT (SPECT) or positron emission
tomography (PET) are increasingly used in the early diagnosis of PD(Niethammer, Feigin, &
Eidelberg, 2012), the adoption of these techniques is still low due to factors such as high cost and
limited accessibility (Gelb, Oliver, & Gilman, 1999; Massano & Bhatia, 2012). Since the motor
symptoms of PD can occur in other disorders as well physicians need to rule out symptoms
including, but not limited to, dementia preceding motor symptoms, hallucinations unrelated to
medications, freezing, supranuclear gaze palsy, severe symptomatic dysautonomia, prominent
postural instability, unusual features early in the clinical course and other documented conditions
known to produce parkinsonism such as focal brain lesions. Also, responsiveness to treatment with
levodopa or a dopamine agonist is another indicator for PD diagnosis. Previous studies have
indicated that around 94% to 100% of patients whose PD diagnosis was confirmed by autopsy
have responded to levodopa therapy (Hughes, Daniel, & Lees, 1993; Louis, Klatka, Liu, & Fahn,
1997).
The National Institute of Neurological Disorders and Stroke (NINDS) outlined a diagnostic
criteria for PD diagnosis. Diagnosis of PD is considered as probable if any three of the four cardinal
symptoms are present, no symptoms of competitive diagnoses were present for a duration of more
than three years and the patients shows a substantial and sustained response to levodopa or a
dopamine agonist. The diagnosis is considered as possible if only two of the cardinal symptoms
were present, no symptoms of competitive diagnoses were present for less than three years and the
2

patient has either substantial and sustained response to levodopa or a dopamine agonist or have
not adequately been treated with them (Gelb et al., 1999).
Epidemiology
PD is the second most common neurodegenerative disorder in the US after Alzheimer’s
disease (De Lau & Breteler, 2006). It is also the second most common movement disorder after
essential tremor (Alves, Forsaa, Pedersen, Gjerstad, & Larsen, 2008; Tanner & Aston, 2000). The
incidence of PD is low before 50 years of age and increases with age up to 80. The median agestandardized incidence rate of PD in the US was estimated to be 14 per 100,000 people among the
overall population and 160 per 100,000 in individuals aged 65 years and above (Hirtz et al., 2007).
The prevalence of PD is more common in men when compared to women with the lifetime risk of
developing PD being 2.0% in men and 1.3% in women (Elbaz et al., 2002). This study estimated
that the total number of PD patients in the US was around 349,000 in the year 2005. Another study
using the Medical Expenditure Panel Survey (MEPS) data estimated the prevalence rate of PD in
population aged 45 and below to be 0.01% and in population over age 65 the prevalence rate was
1.2%. This study estimated that the total no of PD patients in 2010 were 630,000 which is projected
to reach 819,000 by 2020, 1.06 million by 2030, 1.24 million by 2040 and 1.34 million by 2050
(Kowal, Dall, Chakrabarti, Storm, & Jain, 2013).
Previous epidemiological studies have reported inconsistent results about the distribution
of PD by race in the US. Some studies have indicated that the prevalence of PD is higher in whites
compared to non-whites (Kurtzke & Goldberg, 1988; Lanska, 1997; Lilienfeld et al., 1990;
Wooten, Currie, Bovbjerg, Lee, & Patrie, 2004) while one study conducted in Northern Manhattan
found a higher incidence in African Americans compared to Hispanics and whites (Mayeux et al.,
1995). Another study using Kaiser Permanente Medical Care Program (KPMCP) database found
3

that the incidence of PD is highest in Hispanics followed by Asians, non-Hispanic whites and
African Americans (Van Den Eeden et al., 2003).
The prevalence of PD is very high among Medicare beneficiaries. A retrospective
observational study by Willis et al. found that the mean annual incidence from 2002 to 2005 was
445.9 per 100,000 population and the mean prevalence was 1,588.43 per 100,000 Medicare
population. This study also found that the incidence of PD is higher in non-Hispanic whites when
compared to other racial groups in the US. In terms of geographic region, Midwest and Northeast
regions were found to have higher incidence and prevalence of PD (Wright Willis, Evanoff, Lian,
Criswell, & Racette, 2010).
Treatment
There are no available therapies that can alter the underlying neurodegenerative process
involved in PD (AlDakheel, Kalia, & Lang, 2014). Due to the lack of such therapies, symptomatic
treatment is provided to patients to improve their physical, physiological morbidity and quality of
life. The current interventions for PD management include pharmaceutical products, surgery and
physical therapy (Lang & Lees, 2002). Pharmacological treatment is initiated in patients who begin
to experience functional impairment and social embarrassment due to symptoms and the choice of
therapy depends on age of onset and specific symptoms (Connolly & Lang, 2014). In patients with
mild motor symptoms, treatment can be initiated with a monoamine oxidase type B inhibitor
(MAOBI). In patients with impairment in activities of daily living, treatment is usually started with
levodopa or a dopamine agonist. Although clinical trials have shown that levodopa has greater
symptomatic benefit and lesser side effects when compared to dopamine agonists (Ferreira et al.,
2013) there is growing evidence of better efficacy and lesser incidence of motor complications of
dopamine agonists in early PD patients (Holloway et al., 2004; Rascol et al., 2000). Other drugs
4

like anticholinergics, amantadine and beta blockers are also used to initiate treatment in PD
patients to avoid levodopa-related motor complications.
Surgical treatment options of PD include deep brain simulation (DBS) or neural
transplantation. Currently three areas in the brain are usually targeted by surgery: globus pallidus
interna (Gpi), the subthalamic nucleus (STN), and ventralis intermedius nucleus of the thalamus.
While Gpi and STN are used to improve overall PD symptoms, a surgery in the ventralis
intermedius area of brain is used in the treatment of tremor (Eskandar, Cosgrove, & Shinobu, 2001;
Walter & Vitek, 2004).
Physical therapy and psychosocial counseling is provided to PD patients to improve their
overall quality of life and reduce their dependency on care givers. Physical therapy in PD patients
aims to prevent physical inactivity and falls (Lang & Lees, 2002).
Comorbidities
PD is usually associated with several comorbid conditions since the typical onset of PD is
usually between 60 to 70 years of age and the prevalence of age-related comorbid conditions is
very high in the population after 60 years of age. Some of the common comorbid disorders of PD
include anxiety, depression and sleep disorders (Bergamasco, 2003; Martignoni et al., 2004). A
Canadian study using data from the Canadian Community Health Survey (CCHS) found that
urinary incontinence and arthritis were most frequent comorbidities which resulted in an
incremental burden on PD patients. The study had shown that comorbidities of PD affected the
health status of PD patients in terms of ambulation, dexterity and cognition (Pohar & Jones, 2009).
A hospital based longitudinal study found that the most frequent comorbid events in PD patients
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were trauma (30.5%) which is mostly due to falls and vascular disorders (29.3%) (Martignoni et
al., 2004).
Burden associated with PD
Economic burden
The high prevalence of PD along with the ageing population is expected to impose an
increasing social and economic burden on the patients, caregivers and the overall US healthcare
and social support systems (De Lau & Breteler, 2006; Mateus & Coloma, 2013). Previous research
has indicated that the burden of illness increases with PD disease severity along with a decrease in
productivity (Chrischilles, Rubenstein, Voelker, Wallace, & Rodnitzky, 1998). In 2010, the direct
cost to the US healthcare system incurred by PD patients was estimated to be $14 billion. The
average per patient burden of PD care was estimated to be $22,800 annually. The total indirect
costs due to PD were estimated at $6.3 billion which translates to approximately $10,000 per
person. The study also found that the direct economic burden of PD is $8 billion higher than
patients without PD (Kowal et al., 2013). Other studies have estimated that the total cost of PD to
the US healthcare system ranged from $24 billion to $35 billion (Huse et al., 2005; Whetten‐
Goldstein, Sloan, Kulas, Cutson, & Schenkman, 1997).
Noyes et al. (2006) used the 1992–2000 Medicare Current Beneficiary Survey to evaluate
the economic burden of PD among Medicare beneficiaries. The study found that Medicare
beneficiaries with PD have a significantly higher healthcare costs when compared to beneficiaries
without PD ($18,528 vs. $10,818). The likelihood of using medical care was 277% higher in PD
patients and the likelihood of using long term care and Home Health care was 280% and 108%
higher respectively (Noyes, Liu, Li, Holloway, & Dick, 2006). The direct costs and survival in
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Medicare beneficiaries with early PD were previously studied. This study estimated that early PD
patients have an excess cost of $2,399 in the one year period following diagnosis (Kaltenboeck et
al., 2012). A retrospective database study in Medicare beneficiaries also showed that PD patients
were more likely to have inpatient stays, skilled nursing facility (SNF) visits, Hospice visits and
part D pharmacy visits when compared to non PD patients indicating higher healthcare resource
use in PD patients in Medicare (Xie et al., 2015).
Patients with PD were estimated to have incurred $8.1 billion excess healthcare costs when
compared to patients without PD. Of the $8.1 billion excess healthcare costs in PD patients,
Medicare paid for approximately 24% ($1.9 billion). The excess healthcare costs in PD patients
pose a significant burden to Medicare due to the high prevalence of PD in Medicare beneficiaries
(Kowal et al., 2013).
Quality of life and mortality
PD has a significant negative impact on patient’s quality of life (QoL). The impact of PD
on patient’s Health Related Quality of Life (HRQoL) begins with the onset of motor symptoms
which reduce the patient’s ability in performing activities of daily living (ADL) (Dodel, Berger,
& Oertel, 2001). Depression and cognitive impairment are the main predictors of QoL in PD
patients while physical, medication-related, and cognitive/psychiatric symptoms can also be
significant predictors of QoL in PD patients as well (Rahman, Griffin, Quinn, & Jahanshahi, 2008).
Data from the National Vital Statistic Report indicate that PD was the 14th leading cause
of death in the United States in 2013. The unadjusted death rate was 8.0 per 100,000 population
and the overall age-adjusted death rate due to PD was 7.3 per 100,000 population. The death rate
due to PD increases exponentially after age 65. The unadjusted death rate in population aged 65 to
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74 was 12.7 per 100,000 and increased to 78.5 per 100,000 in the population of 75 to 84 years. In
age groups 85 and over, the death rate due to PD was 231.6 per 100,000 population (Murphy, Xu,
Kochanek, & Bastian, 2016).
Results from previous studies indicate that people who die with PD were older and also
had higher comorbidities. Lethbridge et al. conducted a study using the death certificate database
in Canada. They found that the most frequent comorbidities leading to death among PD patients
were Alzheimer’s disease/dementia (26.2%), pneumonia (22.3%), stroke (14.2%), ischemic heart
disease (13.4%) and cancer (11.1%). The higher likelihood of having dementia or pneumonia in
PD patients who died also has implications on the end of life (EOL) care for PD patients
(Lethbridge, Johnston, & Turnbull, 2013).
The rate of mortality among elderly PD patients is also significantly higher when compared
to Medicare beneficiaries without PD. The hazard ratio (HR) for early PD patients, PD patients
with ambulatory assistance device, PD patients in skilled nursing facilities was 1.43 (p < 0.001),
2.37 (p < 0.001) and 3.34 (p < 0.001) respectively which indicates the higher risk of death in PD
patients when compared to patients without PD (Kaltenboeck et al., 2012).
End of life care in PD
Palliative care is usually provided to patients during the end of life period. However, in the
case of PD treatment, palliative care need not to be considered as terminal care, since palliative
care usually starts before the terminal or end of life phase in patients who no longer respond to
treatments. Palliative care is initiated when patients are unable to tolerate dopaminergic therapy,
unsuitable for surgery or when advanced comorbidities are present (Clarke et al., 2006; MacMahon
& Thomas, 1998). The mean duration of PD was estimated to be 14.6 years of which palliative
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care is usually provided for 2.2 years (MacMahon, Thomas, & Campbell, 1999). Advanced PD
patients are treated with interventions such as DBS surgery, intraduodenal levodopa infusion or
apomorphine infusion. But these therapies are not indicated for end-stage PD patients since they
can no longer tolerate the treatment (Thomas & MacMahon, 2004b). While early palliative care
aims at minimizing dyskinesia and improving motor function of the patient, end-stage palliative
care is focused on treating predominant non-motor symptoms and improving patient’s quality of
life. The common non-motor symptoms in end-stage PD patients include psychosis, depression,
cognitive complications, sleep disturbance, apathy, autonomic dysfunction, orthostatic
hypotension, gastrointestinal disorders, urologic dysfunction, pain, dysphagia and pressure ulcers
(Lokk & Delbari, 2012).
In the initial stages of PD treatment, patients are usually supported by family caregivers.
However, as the disease progresses patient’s disability increases which leads to more dependency,
and symptoms such as depression, hallucinations and falls get worse and thereby leading to
increased caregiver burden. Such symptoms often lead the PD patients to seek institutional care
(Lökk, 2008). Institutional care usually aims to prevent further complications and provide
symptom relief. The focus of institutional care gradually changes from life prolonging therapy to
palliative care (Thomas & MacMahon, 2004a).
End of life costs in PD
End of life costs in PD have been understudied. There were no studies in the US which
looked at the end of life costs in PD patients. However, previous research has shown that nearly
30% of Medicare spending is spent on the 5% to 6% of patients who die in that year (Emanuel &
Emanuel, 1994). Another study found that the average medical expenditure in the one year prior
to death is $37,581 when compared to an average cost of $7,365 during the prior years (Hoover,
9

Crystal, Kumar, Sambamoorthi, & Cantor, 2002). Around 38% of Medicare beneficiaries had
nursing home stay and 19% of Medicare beneficiaries used Hospice in the last year of their life
(Hogan, Lunney, Gabel, & Lynn, 2001). These studies indicate that there is an excessive burden
of end of life costs on Medicare, in general.
Need for the Study
Due to the increasing prevalence of PD there is a significant burden on the US healthcare
system. Coupled with the ageing population, chronic nature of PD, the burden of PD on US
healthcare and social support system is projected to be significantly higher in the future. Hence it
is important to understand the burden of PD throughout the disease course so that treatment
priorities can be appropriately set and the value of PD therapies can be measured (Kaltenboeck et
al., 2012). While previous studies have assessed the costs of PD during the early course of disease
such as the diagnosis and maintenance phase, no studies have assessed the costs of PD patients
during the palliative phase and the end of life period.
Since palliative phase in PD starts with the worsening of symptoms when patients do not
respond to any of the treatment interventions, palliative phase does not imply end of life period in
PD patients. However, end-stage palliative care is usually provided during the end of life period.
While previous studies have indicated that the average duration of palliative phase is 2.2 years,
there is limited information in the literature regarding the average duration of end of life care
provided to terminal PD patients. Also, there is a further need to understand the demographic and
health related predictors of end of life costs such as age, race, and comorbidities in order to
understand the drivers of end of life costs in the PD patients.
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In addition, the impact of place at death on the end of life costs in PD patients is unknown.
Considering the high spending of Medicare (30%) on 5% to 6% of patients who die in that year
(Marshall, McGarry, & Skinner, 2011), it is essential to understand the drivers of end of life costs
along with the impact of place at death on end of life costs in PD patients to develop strategies to
reduce end of life costs without compromising on quality of care.
Specific Aims and Objectives
1. Use Joinpoint regression (piecewise regression) to identify the duration of the end of life
phase in elderly Medicare patients with Parkinson’s disease
2. To assess the end of life costs in Parkinson’s disease patients enrolled in Medicare
a. To assess the healthcare costs during the end of life phase in patients with
Parkinson’s disease who were enrolled in Medicare
b. To assess the demographic and health related predictors including age, gender, race,
comorbidities of end of life costs in Medicare patients with Parkinson’s disease
c. To assess the incremental end of life costs in Medicare patients with Parkinson’s
disease as compared to those without Parkinson’s disease
3. To evaluate the relationship between place at death and end of life costs in Parkinson’s
disease patients enrolled in Medicare

11
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CHAPTER 2: PAPER 1
Using Joinpoint Regression to Identify the Duration of End of Life Phase in Patients with
Parkinson’s Disease
Introduction
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder which
affects a person’s ability to control their movements, body and emotions. It belongs to a group of
conditions which are referred to as motor system disorders. Although the exact cause of PD is
unknown it is often attributed to the loss of neurons in the substantia nigra region of brain which
leads to reduced dopamine production (Samii, Nutt, & Ransom). PD is also characterized by the
accumulation of a protein, alpha-synuclein, also called Lewy bodies in the brain stem, spinal cord
and cortical regions (Lees, Hardy, & Revesz). Genetic mutations are likely to account for 10% of
the cases while the majority (90%) of the PD is considered sporadic (De Lau & Breteler, 2006).
The primary motor symptoms of PD include tremor, bradykinesia, rigidity and postural instability.
Depression, apathy, sleep disorders and erectile dysfunction are some of the non-motor symptoms
of PD (Chaudhuri & Schapira, 2009; Jankovic, 2008). The progression of PD is generally
measured using a rating scale known as Hoehn and Yahr scale (Hoehn & Yahr, 1967). Based on
this scale, PD progression is classified into five stages. Stages one and two represent the early
stage where initial diagnosis of PD is made and patients experience mild symptoms. Stage three
represents the mid stage where PD symptoms start affecting activities of daily living. Stages four
and five represent the advanced stage of PD where patients experience severe symptoms such as
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falling, poor balance, speech and swallowing problems and cannot perform activities of daily
living (Clarke, Sullivan, & Mason, 2006; Müller et al., 2000).
Palliative care usually refers to care provided to patients with terminal illnesses who no
longer respond to the available treatment options. Palliative care focuses on providing relief from
pain and suffering along with improving the patient’s overall quality of life (Cassel & Field, 1997;
Lo, Quill, & Tulsky, 1999). Palliative care is usually initiated in PD patients who are unable to
tolerate dopaminergic therapy, unsuitable for surgery or when advanced comorbidities are present
(MacMahon & Thomas, 1998). End of life (EOL) is the final stage of life and care provided during
EOL is focused on providing comfort to the patient (Curtis, 2008; Lunney, Lynn, Foley, Lipson,
& Guralnik, 2003; Murray, Kendall, Boyd, & Sheikh, 2005). For terminal diseases such as cancer,
palliative care is usually provided during the EOL phase. In case of PD patients, palliative care
may not be considered as EOL care since it is initiated well before the EOL phase when PD
treatments no longer provide benefits to the patients (Clarke et al., 2006). The diminished benefit
of anti-Parkinson’s medications and other treatments is usually evident during the mid-stage of the
disease. During advanced stage of the disease, non-motor complications such as cognitive
difficulty and dementia become more prevalent and patients may have physical disability,
cognitive decline and other comorbid disorders (Bunting-Perry, 2006; Diamond & Jankovic,
2006). The higher likelihood of dementia and decline in cognitive function among end-stage PD
patients were found to be the primary contributors of increased caregiver burden. The increase in
caregiver burden along with the worsening of symptoms lead PD patients to seek institutional
palliative care (Lökk, 2008).
The mean duration of PD was estimated to be 14.6 years, of which palliative care is usually
provided for 2.2 years (MacMahon, Thomas, & Campbell, 1999). However, the duration of EOL
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in PD patients is less than the 2.2 years since palliative care is initiated prior to the EOL phase.
The duration of EOL depends on the illness trajectory of the disease. While diseases like terminal
cancer often have a short EOL phase where the decline of patient’s health is clearly evident,
diseases such as Alzheimer’s disease and PD have a prolonged time of receding health status
therefore the duration of EOL care in PD patients is not clearly defined (Murray et al., 2005).
Clinical decision aids are used by doctors to identify patients who are nearing the EOL and might
benefit more from EOL care when compared to hospitalization or other treatments such as surgery
or pharmacological treatment. These clinical aids are based on the factors which predicted short
term and medium term death and are used to initiate EOL conversations with the patients. Having
age ≥ 65, having emergency department visits, ICU admissions, hospitalization in the past year,
cognitive impairment, evidence of frailty, evidence of active disease are some of the prominent
factors which indicate that the patient is nearing the EOL phase (Cardona-Morrell & Hillman,
2015; Glare et al., 2008; Levine, Sachs, Jin, & Meltzer, 2007). These factors also indicate that
healthcare costs will start to increase significantly once the patient approaches the EOL phase.
Joinpoint regression is a piece-wise linear regression used in healthcare research to identify the
best-fitting points where statistically significant changes in the trend of disease prevalence,
mortality or costs occur. Also referred to as segmented regression, broken line regression or
multiphase regression with continuity constraint (Kim, Fay, Feuer, & Midthune, 2000), Joinpoint
regression has been used in to identify significant change in the trend of prevalence or mortality ,
as well as to identify the points where statistically significant changes in healthcare cost occur
among patients with cancer, atrial fibrillation and COPD (Govindan et al., 2006; López-Campos,
Ruiz-Ramos, & Soriano, 2014). Identifying the point before death where healthcare costs increase
significantly enables clinicians, patients and their family to identify the EOL phase in PD patients
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(Brown, Riley, Schussler, & Etzioni, 2002b). Hence, the objective of the current study was to
identify the duration of the EOL phase in elderly PD patients enrolled in Medicare through a datadriven approach where healthcare costs are modeled to identify the time point prior to death where
EOL care is initiated.
Methods
Data Source and Study Design
A retrospective study was conducted using 5% random national sample of Medicare
administrative claims data from January 1, 2014 – December 31, 2016 which is available through
the Centers for Medicare and Medicaid services (CMS) for research purposes. The Medicare
claims database contains the claims of healthcare services offered to Medicare beneficiaries
including inpatient, outpatient, long-term care, skilled nursing facility (SNF) and prescription
drugs. The Medicare Beneficiary Summary file contains information related to the patients’
demographics and enrollment status. The Medicare Carrier file contains claims related to the
services provided by non-institutional providers such as physicians, nurse practitioners and
physician assistants. Outpatient file contains the claims related to the services performed by
institutional outpatient providers like hospitals, renal dialysis facilities and community mental
health centers etc. Inpatient and SNF services claims were provided in the MedPAR files. These
files contain procedure codes of services which were classified using the Current Procedural
Terminology (CPT) along with International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9 or ICD-10 diagnosis codes and the amount reimbursed for the services.
Records for prescription drugs dispensed under Medicare part D were included in the Part D Drug
Event (PDE) file. An encrypted beneficiary identification number was used to link the claims from

20

all files. The study was approved by the Institutional Review Board (IRB) of the University of
Mississippi.
Patient selection
The sample for this study contained Medicare beneficiaries who: (1) were ≥ 65 years of
age as of January 1, 2014 (2) who died during the one year period between January 1, 2016 to
December 31, 2016 (3) who had continuous enrollment in Medicare Parts A, B, & D from January
1, 2014 until death. Patients with PD were identified from administrative claims databases using
ICD-9-CM/ICD-10-CM diagnosis codes from 2014 to 2016. Previously published approaches to
identify PD relied on ICD-9 diagnosis codes 332.0, 332.1, 333.0, 333.1 in medical claims and the
use of levodopa from pharmacy claims. However, the sensitivity of these approaches was less than
ideal varying from 66.0% to 89.2% (Butt et al., 2014; Noyes, Liu, Holloway, & Dick, 2007;
Szumski & Cheng, 2009). In the current study, the identification of Medicare beneficiaries with
PD was based on the approach outlined by Szumski et al. (2009). Patients with at least two medical
claims with ICD-9 diagnosis code of 332.0 or ICD-10 diagnosis code of G20 in the one-year period
prior to index date were identified as PD patients. This approach of identifying patients with PD
was found to have a sensitivity of 89.2% and a positive predictive value (PPV) of 79.4% (Szumski
& Cheng, 2009). Patients who were enrolled in managed care plans, patients with dual eligibility
and patients with end stage renal disease (ESRD) (ICD-9-CM code 585.6, ICD-10 code N18.6) or
cancer (ICD-9-CM/ICD-10-CM codes presented in Table 1) were excluded from the study. The
date of death was identified from the Medicare Beneficiary Summary file and was considered as
the index date. A diagrammatic representation of patient selection was provided in Figure 1.
Analysis
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The baseline descriptive characteristics for all subjects were reported using means and
standard deviations for continuous variables, and number and percentages for categorical
variables. Joinpoint regression analysis was performed using Joinpoint regression software, a
software program developed by the Surveillance Research Program of the National Cancer
Institute (NCI) (Joinpoint regression program, NCI, Bethesda, MD). All-cause healthcare costs
were calculated as the sum of costs incurred towards inpatient visits, outpatient visits, emergency
department (ED) visits, home health visits, hospice visits and pharmacy prescriptions. Average
monthly all-cause costs was aggregated and modeled backwards from the date of death to the
previous 24 months. The model selection for Joinpoint regression analysis was informed by the
Cook-Weisberg test for heteroscedasticity and the Breusch-Godfrey LM test for autocorrelation.
A Joinpoint is a point of inflection where statistically significant change in the trend of monthly
costs occurs. The study used a minimum of 1 joinpoints to a maximum of 4 joinpoints to identify
the best fit of data (Kim et al., 2000). The joinpoints prior to death was used to identify the duration
of EOL phase in PD patients. In order to identify the best fit of the data, a sequential algorithmbased method called grid search method was used. Statistical Analysis Software (SAS) version 9.4
(SAS Institute Inc., Cary, NC) was used for data management in the study.
Results
A total of 1,178 PD patients who died during the study index period met the study inclusion
criteria (Figure 1). Mean age of these patients was 83.6 (± 7.3) years with a high proportion of
patients in the age group 86 years and older (43.1%). The percentage of men (52.6%) is slightly
higher than women and majority of the patients were non-Hispanic white (94.3%). Average
comorbidity burden, as measured by Charlson comorbidity index score (CCI) was 3.8 (± 2.2) and
more than half of the patients had at least 4 or more CCI score indicating high comorbidity burden
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in these patients. The most frequent baseline comorbidities were dementia (77.3%), stroke (59.6%)
and congestive heart failure (46.1%). The description of baseline demographic and clinical
characteristics of study sample was presented in Table 2.
Average all-cause monthly costs were lowest during the 24th month prior to death ($4,661
± $13,706) and increased as the patient neared end of life with highest average monthly costs
during the 1-month period prior to death ($28,487 ± $54,097). Average costs by month was found
to have serial correlation based on results from Bresuch-Godfrey LM test and was also found to
have heteroskedasticity.
Results from the Joinpoint regression model indicate that there is a statistically significant
inflection point in the trend of monthly costs at month 3 (monthly percent change [MPC]: 30.86%;
confidence interval [CI]: 51.1% to 21.5%) and month 9 (MPC: 10.78%; CI: 14.9% to 6.5%) prior
to death (Figure 2). Based on these results and clinical judgement, the duration of end of life period
in PD patients was identified as the 9-month period prior to death. In addition, all-cause costs
during the 3-mon EOL period were assessed as sensitivity analysis.
All-cause healthcare costs along with the components of costs were assessed during the 3month and 9-month period prior to death and the results are presented in Table 3. Mean (SD) allcause healthcare costs during the 3-month period prior to death was estimated to be $20,576
(20,474). Average costs were driven by inpatient costs [Mean (SD): $11,810 (20,474)] followed
by costs in a palliative care setting [Mean (SD): $4,815 (1,502)]. All-cause healthcare costs during
the 9-month period prior to death were estimated to be $46,339 (37,863) and were driven by
inpatient costs [Mean (SD): $21,252 (30,845)] followed by costs in palliative care setting [Mean
(SD): $11,810 (20,474)].
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Discussion
Using a data-driven Joinpoint regression approach, we found that there is a significant
change in the trend of all-cause healthcare costs at the 3-and 9-month time points prior to death
among Medicare beneficiaries with PD which indicates a possible shift in the focus of patient and
family from active treatment to palliative care. Considering the high Medicare spending in the
final year of patient’s lives (one-fourth of overall Medicare expenditures) there is increased focus
in understanding costs in Medicare patients during their EOL period (Duncan, Ahmed, Dove, &
Maxwell, 2019). There is no consistent basis to define EOL phase and prior studies defined EOL
phases arbitrarily or based on clinical judgement (Brown, Riley, Schussler, & Etzioni, 2002a).
Hence, our study used a data-driven approach using Joinpoint regression which can provide a basis
for identification of phases of care in PD patients. Our study identified that there is significant
change in trend of costs during months 3 and 9 prior to death. Based on clinical judgement, our
study will consider the 9-month period prior to death as EOL phase in PD patients. The 9-month
EOL phase in PD patients is longer than the 3-mon or 5-mon period prior to death used as EOL
period using a data-driven approach in patients with metastatic breast cancer and metastatic
melanoma respectively (Atkins, Coutinho, Nunna, Gupte-Singh, & Eaddy, 2018; Brown et al.,
2002a).
To our knowledge, our study is the first study to use a data-driven approach with Joinpoint
regression to estimate the duration of EOL phase in progressive neurodegenerative diseases such
as PD.
Our study estimated that the average 3-month end of life costs for elderly PD patients was
$20,576. The EOL costs were lower than EOL costs in cancer patients which ranged from $24,073
during the 3-month period prior to death in ovarian cancer patients to around $32,000 during the
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3-month period prior to death in metastatic breast cancer patients (Bramley, Antao, Lunacsek,
Hennenfent, & Masaquel, 2016; Urban, He, Alfonso, Hardesty, & Goff, 2018). The 9-month EOL
costs in our study were estimated to be $46,339, which were significantly lower than the 6-month
EOL costs estimated in a sample of patients with malignant cancers to be $74,212 possibly due to
the high costs associated with cancer treatments such as chemotherapy, immuno-oncology
treatments which require hospitalizations along with supportive care therapies in cancer patients
(Chastek et al., 2012). While EOL costs in PD patients were lower than cancer patients, costs were
higher when compared to a general sample of Medicare patients in the US. All-cause costs in 6month EOL period in general sample of Medicare patients was estimated to be $18,500 which is
lower than both the 3-mon EOL period and 9-month EOL period costs in PD patients. These results
indicate that EOL costs are higher in PD patients when compared to a general sample of Medicare
population even after adjusting for inflation which is possibly due to the lower use of acute care
or SNF services in EOL period in this sample of general Medicare patients (Bekelman et al., 2016).
This study has several strengths. First, the current study used a data-driven approach using
Joinpoint regression to model healthcare costs during the months prior to death and identify the
points of inflection where there is a significant change in trend of costs. We used clinical
judgement along with the data-driven approach to identify the EOL period in PD patients in
contrast with previous studies which used clinical judgement only. Second, the study used
Medicare administrative claims data to assess healthcare costs in PD patients. Since the prevalence
of PD is significantly higher in patients aged 65 or more, the use of a Medicare sample provides
the opportunity to assess the real-world costs among a general sample of elderly PD patients
receiving care in real world clinical settings in the US. Third, the availability of reliable death
information of patients in Medicare administrative claims data through the social security

25

administration provides a better estimate of EOL costs when compared to commonly used proxy
algorithms for death (Bert Kestenbaum, 1992; Bertram Kestenbaum & Reneé Ferguson, 2002).
Death is identified in the proxy algorithms using hospitalization and ED visits for a life threatening
event followed by loss of enrollment for insurance benefits. This approach may overinflate costs
in the EOL period as patients have significant costs associated with the life threatening event
(Atkins et al., 2018; Joyce et al., 2004). However, results from this study also should be interpreted
in light of certain limitations. Current Medicare administrative claims data does not include any
information about patients enrolled in Medicare advantage or supplemental Medicare plans and
thus may not be representative of non-FFS Medicare patients. It should be noted that although the
current study used a data driven approach to identify the EOL phase among elderly patients with
PD, clinical judgement should be used in conjunction with the data-driven approach to determine
the duration of EOL phase in PD patients. Also, the current study did not assess costs in PD patients
after their initial diagnosis and thus may not support estimation of initial phase of care in PD
patients.
Conclusion
This study also forms a basis to identify phases of PD which can help build phase-based
costing models. Phase-based costing is a novel approach where the duration of disease is divided
into several phases such as initial, interim and end of life phase and average costs are estimated
during each phase and the mean lifetime costs of disease are calculated (Wijeysundera, Wang,
Tomlinson, Ko, & Krahn, 2012). In the current literature, while phase-based costing has been
widely used to assess lifetime costs of oncology conditions (Aly, Clancy, Ung, Agarwal, & Shah,
2018; Atkins et al., 2018; Liu et al., 2016). the use of phase-based costing approaches in nononcology conditions is limited since the overall duration of some of these conditions may span
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over several years (Tawfik et al., 2016). PD, being a progressive neurodegenerative disorder with
a mean duration of PD to be 14.6 years (MacMahon et al., 1999), may be required to be divided
into more than three phases. Further studies with longer follow-up periods are required to identify
phases of care during early stages of PD, assess the costs during these phases so that phase-based
costing models are developed to estimate life time costs of PD.
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Table 1.1: ICD-9-CM and ICD-10 codes for identification of cancer
ICD-9-CM code
Description
Malignant Neoplasm Of Lip, Oral Cavity, And
140.xx - 149.xx
Pharynx
Malignant Neoplasm Of Digestive Organs And
150.xx - 159.xx
Peritoneum
Malignant Neoplasm Of Respiratory And Intrathoracic
160.xx - 165.xx
Organs
Malignant Neoplasm Of Bone, Connective Tissue,
170.xx - 176.xx
Skin, And Breast
179.xx - 189.xx
Malignant Neoplasm Of Genitourinary Organs
190.xx - 199.xx
Malignant Neoplasm Of Other And Unspecified Sites
Malignant Neoplasm Of Lymphatic And
200.xx - 209.xx
Hematopoietic Tissue
230.xx - 234.xx
Carcinoma In Situ
235.xx - 238.xx
Neoplasms Of Uncertain Behavior
239.xx
Neoplasms Of Unspecified Nature
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Table 1.2. Characteristics of Parkinson's disease (PD)
patients who died during the study index period
Demographic and clinical
characteristics
Age in years, Mean (SD)
Age Group (N, %)
65-70
71-75
76-80
81-85
>85 years
Gender (N, %)
Male
Female
Ethnicity (N, %)
Caucasian
African American
Other
Region (N, %)
Northeast
South
Midwest
West
Other
CCI (Mean, SD)
CCI category
0
1
2
3
4+
Comorbidities of interest
AZ
Dementia
Pneumonia
Stroke
CHF

All Parkinson'
disease patients
(N = 1,178)
83.6

(7.3)

67
114
185
304
508

(5.7%)
(9.7%)
(15.7%)
(25.8%)
(43.1%)

620
558

(52.6%)
(47.4%)

1111
37
30

(94.3%)
(3.1%)
(2.5%)

213
445
311
207
2
3.79

(18.1%)
(37.8%)
(26.4%)
(17.6%)
(0.2%)
(2.2)

71
121
165
206
615

(6.0%)
(10.3%)
(14.0%)
(17.5%)
(52.2%)

331
911
267
702
543

(28.1%)
(77.3%)
(22.7%)
(59.6%)
(46.1%)
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Table 1.3. All-Cause healthcare costs during the 3-month and 9-month
period prior to death in patients with PD
All PD Patients
N = 1,176
Direct Healthcare Costs
All-cause Costs During 3-mon EOL
Total costs
Inpatient costs
Outpatient costs
Pharmacy costs
Palliative care costs

$20,576
$11,810
$3,065
$886
$4,815

($20,474)
($18,518)
($3,511)
($2,116)
($1,502)

All-cause Costs During 9-mon EOL
Total costs
Inpatient costs
Outpatient costs
Pharmacy costs
Palliative care costs

$46,339
$21,252
$6,355
$2,950
$10,396

($37,863)
($30,845)
($5,974)
($6,270)
($12,065)
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Figure 1.1: Patient selection

Medicare patients who died between January 1, 2014 and December 31, 2016 were
identified and date of death was considered as index date (N = 330,703)

Patients with at least two claims with ICD-9/ICD-10 PD diagnosis codes in the one-year
period prior to index date were defined as PD patients (N = 13,415)

Patients who were at least 65 years age as of January 1, 2014, continuously enrolled in
Medicare Parts A, B & D throughout the study period and did not enroll in managed
Medicare plans or had ESRD (N = 3,241)
Patients without at least 1 claim with a diagnosis code for cancer during the study period
(N = 2,358)

Patients whose index date is between January 1, 2016 and December 31, 2016 (N = 1,178)
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Figure 1.2: Duration of EOL phase in PD patients
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CHAPTER 3: PAPER 2
Predictors of End of Life Healthcare Costs in Medicare Beneficiaries with Parkinson’s
Disease
Introduction
Parkinson's disease (PD) is a progressive neurological disorder which is characterized by
various motor and non-motor symptoms which can impact the patient’s functional status. It
belongs to a group of conditions which are referred to as motor system disorders. The exact cause
of PD is unknown, but the reduced dopamine production due to degeneration of dopamineproducing cells in the sustantia nigra region of brain is believed to be the main cause of PD (Samii,
Nutt, & Ransom). PD is usually diagnosed by the asymmetric occurrence of cardinal symptoms
which include tremor, bradykinesia, rigidity (Jankovic, 2008). There are no available therapies that
can alter the underlying neurodegenerative process involved in PD (AlDakheel, Kalia, & Lang,
2014). Due to the lack of curative therapies, symptomatic treatment is provided to PD patients to
manage symptoms and improve quality of life. The current interventions for PD include
pharmaceutical treatment, surgery and physical therapy (Lang & Lees, 2002). The course of PD
usually starts with a diagnosis and maintenance phase where complete symptom relief is obtained
by pharmacological treatment. It is followed by a complex phase where motor complications and
neuropsychiatric complications occur. The disease course ends with a palliative phase where end
of life (EOL) care is provided (Clarke, Sullivan, & Mason, 2006; Lokk & Delbari, 2012).
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Medicare beneficiaries with PD were found to have incurred significantly higher costs
($18,528 vs. $10,818) when compared to Medicare beneficiaries without PD. The likelihood of
using medical care services was 277% higher in PD patients and particularly the likelihood of
using long-term care (LTC) services and Home Health care was 280% and 108% higher,
respectively when compared to patients without PD (Noyes, Liu, Li, Holloway, & Dick, 2006).
Also, PD patients were more than two times likely (OR: 2.12, 95% CI: 1.99 to 2.25) to use Home
Health services when compared to patients without PD (Bhattacharjee et al., 2015). A study in
Medicare patients has shown that 73.5% of PD patients were hospitalized, 69.8% used Hospice
services and 44% used skilled nursing facility (SNF) services during the last year of life (Willis et
al., 2012). These studies have shown that the incremental healthcare resource use and costs in
Medicare patients with PD are significant.
PD is usually associated with several comorbid conditions since the typical onset of PD is
between 60 to 70 years of age and the prevalence of age-related comorbid conditions is high in
this population. Some of the common comorbid disorders of PD include anxiety, depression and
sleep disorders (Bergamasco, 2003; Martignoni et al., 2004). A hospital based longitudinal study
reported that the most frequent comorbid events in PD patients were trauma (30.5%) which is
mostly due to falls and vascular disorders (29.3%) (Martignoni et al., 2004). Another study looked
at the prevalence of neurological, cardiovascular and other comorbidities in PD patients who died
(Lethbridge, Johnston, & Turnbull, 2013) and found that PD patients had higher comorbidities
compared to the general population. Alzheimer’s disease (26%), pneumonia (22%), stroke (14%),
chronic ischemic heart disease (13%) and cancer (11%) were found to be the most prevalent
comorbidities in PD patients. While the proportion of patients with comorbidities such as
Alzheimer’s disease, pneumonia and stroke is higher in PD patients when compared to age and
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sex matched sample of non-PD patients, the proportion of patients with ischemic heart disease and
cancer is lower when compared to non-PD patients.
Studies have shown that the use of medical services such as hospital, Home Health, SNF,
LTC or Hospice services in PD patients during the EOL period is generally due to complications
and comorbidities associated with PD rather than PD itself. Terminal PD patients often have
cognitive decline, motor and neuropsychiatric complications therefore resulting in higher
healthcare costs during the EOL period. For example, one study shows that terminal PD patients
were hospitalized for cardiovascular diseases (15%), infections (29.5%) and were rarely
hospitalized for PD itself (4.2%) (Willis et al., 2012). Another study reports that hip fracture and
dementia were significant predictors of using LTC services during the last year of life (Safarpour
et al., 2015).
Previous research has shown that nearly 30% of Medicare annual spending is spent on the
5 to 6% of patients who die in that year (Emanuel & Emanuel, 1994). Another study found that
the average medical expenditure for Medicare patients in the one year prior to death is $37,581
when compared to an average cost of $7,365 during the prior years (Hoover, Crystal, Kumar,
Sambamoorthi, & Cantor, 2002). Elderly Medicare beneficiaries with PD have higher comorbidity
and economic burden when compared to patients without PD (Lethbridge et al., 2013; Martignoni
et al., 2004; Noyes et al., 2006; Safarpour et al., 2015). However, there is a lack of information
about the EOL costs in these patients. Considering the high use of Hospice, SNF/ LTC and Home
Health services during the last year of life of PD patients, we hypothesized that EOL costs in PD
patients will be significantly higher when compared to patients without PD. The current study aims
to assess the healthcare costs of PD patients during the EOL period and estimate the incremental
costs as compared to patients without PD. Furthermore, understanding the drivers of costs during
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the EOL period can assist in the planning of EOL care for PD patients. Hence, the study also aims
to assess the predictors of EOL costs in PD patients enrolled in Medicare.
Methods
Data Source and Study Design
A retrospective matched cohort study was conducted using data from the 5% random
national sample of Medicare administrative claims from January 1, 2014 – December 31, 2016.
The data is made available through the Centers for Medicare and Medicaid services (CMS) for
research purposes. This database contains the claims of healthcare services offered to Medicare
beneficiaries including inpatient, outpatient, long-term care, skilled nursing facility (SNF), Home
Health, Hospice and prescription drugs. The Medicare Beneficiary Summary file contains
information related to patients’ demographics and enrollment status. The Medicare Carrier file
contains claims related to services provided by non-institutional providers such as physicians,
nurse practitioners and physician assistants. Outpatient file contains the claims related to the
services performed by institutional outpatient providers like hospitals, renal dialysis facilities and
community mental health centers. Inpatient, SNF and LTC services claims were provided in the
MedPAR files. These files contain procedure codes of services which were classified using the
Current Procedural Terminology (CPT) along with ICD-9/ICD-10 diagnosis codes and the amount
reimbursed for the services. Records for prescription drugs dispensed under Medicare part D were
included in the Part D Drug Event (PDE) file. An encrypted beneficiary identification number is
used to link the claims. This study obtained approval from the Institutional Review Board (IRB)
of the University of Mississippi.
Patient Selection
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The sample for this study contained Medicare beneficiaries who: (1) were ≥ 65 years of
age as of January 1, 2014 (2) who died during the index period between April 1, 2015 to December
31, 2016 (3) who had continuous enrollment in Medicare Parts A, B, & D from January 1, 2014
until death. Previously published approaches to identify PD relied on ICD-9 diagnosis codes 332.0,
332.1, 333.0, 333.1 in medical claims and the use of levodopa from pharmacy claims. In the current
study, the identification of Medicare beneficiaries with PD will be based on the approach outlined
by Szumski et al. (2007) where patients with at least two medical claims with ICD-9 diagnosis
code 332.0 or ICD-10 diagnosis code G20 in the one-year period prior to index date were identified
as PD patients. This approach was found to have a sensitivity of 89.2% and a positive predictive
value (PPV) of 79.4% (Szumski & Cheng, 2009). In the current study, date of death was identified
from the Medicare Beneficiary Summary file and was considered as the index date. The duration
of EOL period was determined as the 9-month period prior to death using results from the Joinpoint
regression analysis reported in the previous study and the six month period prior to EOL period
was considered as the baseline period. Sensitivity analysis was performed by defining the EOL
period as 3 months prior to death. Patients who were enrolled in managed care plans, patients with
dual eligibility and patients with end stage renal disease (ESRD) or cancer (ICD-9-CM/ICD-10CM codes presented in Table 1) from January 1, 2014 until index date) were excluded. A
diagrammatic representation of patient selection is provided in Figure 1.
Matched Cohorts
PD patients who died between April 1, 2015 and December 31, 2016 were matched on a
1:4 ratio to non-PD patients who died during the same period. Deyo adaptation of Charlson
Comorbidity Index (CCI) was modified by excluding diagnosis codes for cancer and metastases.
Modified CCI was calculated during the baseline period using ICD-9/ICD-10 diagnosis codes from
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MedPAR, Carrier and Outpatient files (Deyo, Cherkin, & Ciol, 1992). PD and non-PD cohorts
were matched using a greedy match algorithm on modified CCI along with age at death (±3 years)
and gender to obtain a comparable comorbidity profile in both cohorts. This approach allowed the
assessment of incremental cost due to PD during the EOL period.
Measures
Outcome Variable
The outcome variables assessed in the study were all-cause healthcare costs. Costs were
measured during the EOL period from the Medicare perspective and hence payments made by
patients such as co-payments and deductibles were not included. All-cause healthcare costs include
payments made for outpatient services, emergency department (ED) visits, inpatient services,
SNF/LTC services, Home Health services, Hospice services and prescription drug costs. Office
visits were defined as claims with place of service codes 11 (office), 22 (outpatient hospital), 71
(state or public health clinic), or 72 (rural health clinic) or procedure codes 99201-99215, 9924199245, 99354-99355, 99381-99429 in the Carrier file and Outpatient file.
Predictors of EOL Costs
The key predictors of EOL costs were the severity of PD and comorbidities. Severity of
PD was assessed in the baseline period through a proxy measure based on the mean daily tablet
load of PD medication approach proposed by Fargel et al. (see Table 2 for the list of PD
medications used). Fargel et al, reported that the mean daily tablet load of early stage PD patients
was 3.2 tablets of PD-related medications. In advanced PD patients the mean daily tablet load
ranged from 8.4 to 9.9 tablets of PD-related medications (Fargel, Grobe, Oesterle, Hastedt, &
Rupp, 2007). In the current study, patients with a mean daily PD-related tablet load of more than
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8, 4 to 7, 3 and less were categorized as advanced PD patients, mid stage PD patients and early
stage PD patients, respectively. The mean daily PD-related tablet load was calculated during the
baseline period as well. Comorbidities include Alzheimer’s disease, dementia, pneumonia, stroke,
ischemic heart disease and congestive heart failure (CHF) were included in the model as predictors.
Demographic predictors included in the study were age, gender, race and geographic region. Age
was calculated at death and was used as a continuous variable. Gender was measured as male or
female. Race was used as a categorical variable and was categorized as non-Hispanic white,
African American and other racial group (including Asian, Hispanic, Native Hawaiian, Pacific
Islander, American Indian or Alaskan Native, or unknown race). Geographic region was
categorized as Northeast, South, Midwest and West.
For the matched cohort analysis comparing EOL costs in the PD and non-PD cohort, the
diagnosis of PD was the primary independent variable of interest. Race, geographic region and
comorbid conditions of interest were controlled for in the model.
Statistical Analysis
All statistical analyses were conducted using Statistical Analysis System (SAS) version 9.4
(SAS Institute Inc., Cary, NC). Descriptive characteristics for the PD cohort and non-PD cohort
were reported using means and standard deviations (SD) for continuous variables and frequencies
and percentages were reported for categorical variables. Generalized linear models were used to
identify the predictors of EOL costs and calculate the incremental all-cause cost burden of PD
patients. Due to the presence of zero values for some patients for inpatient costs, outpatient costs,
pharmacy and palliative care costs, two-part models were used to estimate adjusted costs for these
cost components. The first part of the model used a logistic regression to predict the probability of
observing non-zero costs and the second part of the model was a generalized linear model with
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gamma distribution and log link for recipients with non-zero costs. Final costs estimates were
estimated by multiplying probability of non-zero costs estimated in part one and estimated costs
from part two. Adjusted costs were calculated using LSMEANS option in SAS in both generalized
linear models and two-part models. Pregibon goodness-of-link test was used to examine adequacy
of hypothesized link for the data and Modified Park Test (MPT) was used to identify the
appropriate family of the generalized model. Informed by Pregibon goodness-of-link test and
modified Park’s test, a generalized model with log link and gamma distribution was used to
identify significant predictors of EOL costs in PD patients when compared to age-, sex- and CCImatched non-PD cohort with race, geographic region, Alzheimer’s disease, dementia, pneumonia,
stroke, ischemic heart disease and congestive heart failure as predictors. Costs were adjusted to
2016 USD using the medical component of consumer price index (CPI).
For the matched sample, unadjusted costs were compared using Wilcoxon signed-rank test.
EOL costs between PD cohort and non-PD cohort were compared using generalized linear models.
Adjusted mean all-cause healthcare costs were obtained from the generalized model after
controlling for race, geographic region and comorbidities of interest.
Results
A total of 11,130 patients who died during the index period (Apr 1, 2015 to Dec 31, 2018)
were included in our study. Of these, 2,226 were PD patients and 8,904 patients were non-PD
patients matched on age, gender, and CCI with the PD cohort. The demographic and clinical
characteristics of PD cohort and non-PD were presented in Table 3. The matched PD and non-PD
cohorts were similar in terms of age, gender and comorbidity burden as assessed by CCI. While
non-Hispanic whites comprised on more than 90% of both cohorts, the percentage was higher in
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PD cohort when compared to non-PD cohort (94.4% in PD cohort vs. 91.9% in non-PD cohort, p
<0.0001).
Regarding the comorbidities of interest, prevalence of comorbidities is significantly higher
in PD cohort when compared to non-PD cohort with the exception of CHF. CHF was the most
frequently found comorbidity in the overall cohort and the prevalence of CHF was significantly
higher in the non-PD cohort when compared to PD cohort (52.6% vs. 44.3%, p < 0.0001). The
prevalence of dementia and stroke was significantly higher in the PD cohort when compared to
non-PD cohort. Dementia was present in 75.1% in PD cohort vs 42.8% in non-PD cohort (p <
0.0001) whereas 55.8% in PD cohort vs. 44.6% in non-PD cohort (p < 0.0001) had stroke. The
prevalence of another progressive neurological disorder, Alzheimer’s disease, was significantly
higher in PD cohort when compared to non-PD cohort (16.4% in PD cohort vs. 9.6% in non-PD
cohort, p < 0.0001).
The 9-month EOL costs were significantly higher in PD cohort (unadjusted costs: $45,701
vs. $39,775, p < 0.001; adjusted costs: $48,429 vs. $43,054, p = 0.0324). 9-mon EOL costs were
driven by hospitalization costs in both cohorts (46% in PD cohort and 66% in non-PD cohort). The
percentage of 9-mon EOL costs incurred towards palliative care (home health and hospice) were
significantly higher in PD cohort when compared to non-PD cohort (21% in PD cohort vs. 14% in
non-PD cohort) indicating the higher use and costs incurred towards EOL services in PD patients
when compared to patients with similar age, sex and comorbidity burden. The 9-mon EOL costs
were significantly higher in PD cohort when compared to non-PD patients (β = 0.12, 95% CI: 0.07
to 0.16, p = < 0.0001). While no racial differences were found to be significant, 9-mon EOL costs
were higher in Midwest and Western regions of US when compared to the Northeastern US.
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In terms of comorbidities, Alzheimer’s disease, dementia, pneumonia, stroke and CHF
were found to be significant predictors of 9-month EOL costs. Congestive heart failure is the
strongest predictor of EOL costs with β = 0.47 (95% CI: 0.43 to 0.50, p < 0.0001) followed by
pneumonia (β = 0.30; 95% CI: 0.26 to 0.33, p < 0.0001) and stroke (β = 0.30; 95% CI: 0.26 to
0.33, p < 0.001). Neurological comorbidities such as dementia (β = 0.12, 95% CI: 0.08 to 0.16, p
< 0.0001) and Alzheimer’s disease (β = 0.06, 95% CI: 0.01 to 0.12, p = 0.033) were found to be
significant predictors of EOL costs. These results also indicate that patients with multiple
neurological conditions have significantly higher EOL costs when compared to patients without.
In contrast, results of the sensitivity analysis show that the mean unadjusted all-cause costs
during the 3-month EOL period were significantly lower in PD cohort when compared to non-PD
cohort ($20,769 vs. $21,237, p = 0.0006). However, after adjustment for baseline covariates, mean
all-cause costs were higher in PD cohort when compared to non-PD cohort ($24,248 vs. $23,978,
p = 0.7539), but the difference was not statistically significant.
Results from the generalized model indicate that the 3-mon EOL costs are not significantly
different in PD cohort and non-PD cohort (β = 0.008, 95% CI: -0.04 to 0.06, p = 0.7539). African
Americans were found to have significantly higher EOL costs when compared to non-Hispanic
whites (β = 0.16, 95% CI: 0.07 to 0.25, p = 0.0005). Results from the model also indicate that
patients in Midwest and Western regions of the US have significantly lower 3-mon EOL costs
when compared to patients residing in the Northeast US (β for MW = - 0.11, 95% CI: -0.16 to 0.05, p = 0.0002, β for W: -0.10, p = 0.001).
Discussion
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Results from our study indicate the costs in PD patients were significantly higher when
compared to non-PD patients of comparable demographics and baseline comorbidity burden
during the 9-month EOL period before death. In sensitivity analysis, while the results were not
statistically significant, adjusted 3-month EOL costs were also higher in PD patients when
compared to non-PD patients. Our results indicate that EOL costs in PD patients are driven by
hospitalization costs and palliative care costs where as EOL costs in non-PD cohort are driven by
hospitalizations costs and outpatient visit costs. Due to the nature of PD progression, the intent of
treatment during the EOL period in PD patients shifts to palliative care. As a result, PD-specific
treatments are discontinued in some patients and the focus of treatment shifts to treating
predominant non-motor symptoms of PD (Richfield, Jones, & Alty, 2013). The shift in focus of
treatment to palliative care may have led to lower treatment intensities in advanced PD patients
leading to similar costs of hospitalizations between PD and non-PD cohorts during the EOL period.
This shift in treatment intent also may have led to higher palliative care costs and lower pharmacy
costs in PD patients when compared to non-PD patients. To our knowledge, ours is the first study
to estimate EOL cost burden in PD patients. Our study also reported costs associated with home
health and hospice services along with inpatient, outpatient and pharmacy services among elderly
PD patients. These results indicated the higher cost burden associated with home health and
hospice services in PD patients when compared to non-PD patients.
Annual direct costs in patients with PD during their lifetime was estimated to be between
$10,043 and $12,491 (Huse et al., 2005; O'Brien, Ward, Michels, Tzivelekis, & Brandt, 2009).
Cost estimates during the 9-month EOL period from our study results are $45,701. Considering
that the 9-mon EOL costs are around four times of annual costs during PD patients’ lifetime, we
conservatively estimate that there is more than four-fold increase in the costs during the EOL
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period prior to death when compared with annual costs during the overall course of PD. Also,
results from our study indicate that African Americans had higher EOL costs when compared to
non-Hispanic whites. These racial differences in higher EOL costs are consistent with other studies
which had similar findings about higher EOL costs in African Americans even though per patient
healthcare spending in African Americans enrolled in Medicare is lower than other racial groups
(Hogan, Lunney, Gabel, & Lynn, 2001). In terms of regional disparities, EOL costs in Midwest
and Western regions of the US have significantly lower EOL costs when compared to Northeastern
US. These results are consistent with prior studies which indicated that racial and geographic
disparities influence the treatment choices and access to care during the EOL period (Baicker,
Chandra, & Skinner, 2005; Baicker, Chandra, Skinner, & Wennberg, 2004; Cooper, Rivara, Wang,
MacKenzie, & Jurkovich, 2012).
Informed by literature, our study assessed the association between comorbidities of interest
such as Alzheimer’s disease, pneumonia, stroke, chronic ischemic heart disease and EOL costs
(Lethbridge et al., 2013; Martignoni et al., 2004). While previous literature indicated that cancer
is a highly prevalent comorbidity in PD patients, our study excluded patients with cancer since
EOL costs in cancer patients were studied extensively and including cancer patients can bias the
cost estimates in the sample due to the expensive treatment options for cancer (Kovačević et al.,
2015). PD cohort in our study had prevalent dementia in ~75% of the patients which is consistent
with the literature (Hely, Reid, Adena, Halliday, & Morris, 2008). The high prevalence of dementia
in our study sample also indicates that majority of PD patients in our sample are in advanced stage
of PD since Parkinson’s dementia is a sign of disease progression in PD patients (Dubois et al.,
2007). Results from our study indicate that dementia is associated with significant EOL cost
burden. While the prevalence of neurological comorbidities is in our study sample is in line with
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current literature, the prevalence of cardiovascular comorbid conditions such as CHF, ischemic
stroke was higher in PD patients in our study sample when compared to other studies in PD patients
possibly due to the restriction of sample to patients aged at least 65 years in our study (Lethbridge
et al., 2013).
Our study has several strengths. First, our study was conducted using the 5% Medicare
sample which has the advantage of being representative of Medicare patients from most of the
states in the US. Also, the use of Medicare 5% sample also provides a better tool to understand the
EOL costs in PD patients since the prevalence of PD is highest in older patients aged 65 or older.
In addition, Medicare data contains information on date of death through social security
administration and the availability of accurate information of patient’s death in Medicare database
enables better estimation of EOL costs when compared to studies which use proxy algorithms
based on occurrence of life threatening events and loss of eligibility for benefits to identify date of
death (Atkins, Coutinho, Nunna, Gupte-Singh, & Eaddy, 2018; Joyce et al., 2004; Bert
Kestenbaum, 1992; Bertram Kestenbaum & Reneé Ferguson, 2002). Second, this study excluded
patients with malignant tumors since the EOL costs in cancer patients were significantly higher
than non-cancer patients and were upwards of $70,000 during the 6 months prior to death (Atkins
et al., 2018; Kovačević et al., 2015; Sheffield et al., 2011). However, due to this exclusion criteria,
the study results must be interpreted among PD patients without comorbid cancer. Third, the
availability of hospice and home health services data in Medicare administrative claims enable us
to better understand PD patients’ burden of home health and hospice services when compared to
non-PD cohort.
Our study also has a fair share of limitations. First, our study excluded Medicare patients
with Medicare advantage, supplemental Medicare or dual eligibility due to the non-availability of
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complete data for these patients. Prior studies found that the presence of chronic conditions was
slightly lower in patients enrolled in Medicare advantage plans when compared to Medicare feefor-service plans (Miller, Decker, & Parker, 2016). Hence, our study results may not be
generalizable to all Medicare patients. Also, our study is restricted to patient population 65 years
or older. While the prevalence of PD in patients aged less than 65 years, nevertheless, previous
studies have shown that early onset PD significantly reduces life expectancy (Ishihara,
Cheesbrough, Brayne, & Schrag, 2007) and thus results from our study may not be representative
of PD patients who died before attaining 65 years of age.
Conclusion
In summary, EOL costs among PD patients were significantly higher when compared to
non-PD patients of similar age, gender and CCI. Results from the multivariable analysis also
indicate that the presence of comorbidities during the baseline period significantly affect the costs
during EOL period. Also, results from this study indicate significant racial and geographic
disparities in costs and healthcare utilization provided to the PD patients.

52

BIBLIOGRAPHY

53

AlDakheel, A., Kalia, L. V., & Lang, A. E. (2014). Pathogenesis-targeted, disease-modifying
therapies in Parkinson disease. Neurotherapeutics, 11(1), 6-23.
Atkins, M., Coutinho, A. D., Nunna, S., Gupte-Singh, K., & Eaddy, M. (2018). Confirming the
timing of phase-based costing in oncology studies: a case example in advanced
melanoma. Journal of medical economics, 21(2), 212-217.
Baicker, K., Chandra, A., & Skinner, J. (2005). Geographic variation in health care and the
problem of measuring racial disparities. Perspectives in biology and medicine, 48(1), 42S53.
Baicker, K., Chandra, A., Skinner, J. S., & Wennberg, J. E. (2004). Who You Are And Where
You Live: How Race And Geography Affect The Treatment Of Medicare Beneficiaries:
There is no simple story that explains the regional patterns of racial disparities in health
care. Health affairs, 23(Suppl2), VAR-33-VAR-44.
Bergamasco, B. (2003). Guidelines for the treatment of Parkinson's Disease 2002: Springer.
Bhattacharjee, S., Metzger, A., Tworek, C., Wei, W., Pan, X., & Sambamoorthi, U. (2015).
Parkinson’s Disease and Home Healthcare Use and Expenditures among Elderly
Medicare Beneficiaries. Parkinson’s Disease, 2015.
Clarke, C., Sullivan, T., & Mason, A. (2006). National clinical guideline for diagnosis and
management in primary and secondary care. National Collaborating Centre for Chronic
Conditions Parkinson’s disease.
Cooper, Z., Rivara, F. P., Wang, J., MacKenzie, E. J., & Jurkovich, G. J. (2012). Racial
disparities in intensity of care at the end-of-life: are trauma patients the same as the rest?
Journal of health care for the poor and underserved, 23(2), 857-874.
Deyo, R. A., Cherkin, D. C., & Ciol, M. A. (1992). Adapting a clinical comorbidity index for use
with ICD-9-CM administrative databases. Journal of clinical epidemiology, 45(6), 613619.
Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R. G., Broe, G. A., . . . Gauthier, S.
(2007). Diagnostic procedures for Parkinson's disease dementia: recommendations from
the movement disorder society task force. Movement disorders, 22(16), 2314-2324.
Emanuel, E. J., & Emanuel, L. L. (1994). The economics of dying--the illusion of cost savings at
the end of life. New England Journal of Medicine, 330(8), 540-544.
Fargel, M., Grobe, B., Oesterle, E., Hastedt, C., & Rupp, M. (2007). Treatment of Parkinson's
disease: a survey of patients and neurologists. Clinical drug investigation, 27(3), 207219.
Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M., & Morris, J. G. (2008). The Sydney
multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.
Movement Disorders, 23(6), 837-844.
Hogan, C., Lunney, J., Gabel, J., & Lynn, J. (2001). Medicare beneficiaries’ costs of care in the
last year of life. Health affairs, 20(4), 188-195.
Hoover, D. R., Crystal, S., Kumar, R., Sambamoorthi, U., & Cantor, J. C. (2002). Medical
expenditures during the last year of life: findings from the 1992–1996 Medicare current
beneficiary survey. Health services research, 37(6), 1625-1642.
54

Huse, D. M., Schulman, K., Orsini, L., Castelli‐Haley, J., Kennedy, S., & Lenhart, G. (2005).
Burden of illness in Parkinson's disease. Movement disorders: official journal of the
Movement Disorder Society, 20(11), 1449-1454.
Ishihara, L. S., Cheesbrough, A., Brayne, C., & Schrag, A. (2007). Estimated life expectancy of
Parkinson’s patients compared with the UK population. Journal of Neurology,
Neurosurgery & Psychiatry, 78(12), 1304-1309.
Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology,
Neurosurgery & Psychiatry, 79(4), 368-376.
Joyce, A. T., Iacoviello, J. M., Nag, S., Sajjan, S., Jilinskaia, E., Throop, D., . . . Alexander, C.
M. (2004). End-stage renal disease-associated managed care costs among patients with
and without diabetes. Diabetes Care, 27(12), 2829-2835.
Kestenbaum, B. (1992). A description of the extreme aged population based on improved
Medicare enrollment data. Demography, 29(4), 565-580.
Kestenbaum, B., & Reneé Ferguson, B. (2002). Mortality of the extreme aged in the United
States in the 1990s, based on improved Medicare data. North American Actuarial
Journal, 6(3), 38-44.
Kovačević, A., Dragojević-Simić, V., Rančić, N., Jurišević, M., Gutzwiller, F., Matter-Walstra,
K., & Jakovljević, M. (2015). End-of-life costs of medical care for advanced stage cancer
patients. Vojnosanitetski pregled, 72(4), 334-341.
Lang, A. E., & Lees, A. (2002). Management of Parkinson’s disease: an evidence-based review.
Mov Disord, 17(Suppl 4), S1-S166.
Lethbridge, L., Johnston, G. M., & Turnbull, G. (2013). Co-morbidities of persons dying of
Parkinson's disease. Progress in palliative care, 21(3), 140-145.
Lokk, J., & Delbari, A. (2012). Clinical aspects of palliative care in advanced Parkinson’s
disease. BMC palliative care, 11(1), 20.
Martignoni, E., Godi, L., Citterio, A., Zangaglia, R., Riboldazzi, G., Calandrella, D., . . . Nappi,
G. (2004). Comorbid disorders and hospitalisation in Parkinson’s disease: a prospective
study. Neurological Sciences, 25(2), 66-71.
Miller, E. A., Decker, S. L., & Parker, J. D. (2016). Characteristics of Medicare Advantage and
fee-for-service beneficiaries upon enrollment in Medicare at age 65. Journal of
Ambulatory Care Management, 39(3), 231-241.
Noyes, K., Liu, H., Li, Y., Holloway, R., & Dick, A. W. (2006). Economic burden associated
with Parkinson's disease on elderly Medicare beneficiaries. Movement Disorders, 21(3),
362-372.
O'Brien, J. A., Ward, A., Michels, S. L., Tzivelekis, S., & Brandt, N. J. (2009). Economic burden
associated with Parkinson disease. Cerebrovascular Diseases, 21.
Richfield, E. W., Jones, E. J., & Alty, J. E. (2013). Palliative care for Parkinson’s disease: a
summary of the evidence and future directions. Palliative medicine, 27(9), 805-810.
Safarpour, D., Thibault, D. P., DeSanto, C. L., Boyd, C. M., Dorsey, E. R., Racette, B. A., &
Willis, A. W. (2015). Nursing home and end-of-life care in Parkinson disease. Neurology,
85(5), 413-419.
Sheffield, K. M., Boyd, C. A., Benarroch‐Gampel, J., Kuo, Y. F., Cooksley, C. D., & Riall, T. S.
(2011). End‐of‐life care in Medicare beneficiaries dying with pancreatic cancer. Cancer,
117(21), 5003-5012.
Szumski, N. R., & Cheng, E. M. (2009). Optimizing algorithms to identify Parkinson's disease
cases within an administrative database. Movement Disorders, 24(1), 51-56.
55

Willis, A. W., Schootman, M., Kung, N., Evanoff, B. A., Perlmutter, J. S., & Racette, B. A.
(2012). Predictors of survival in patients with Parkinson disease. Archives of neurology,
69(5), 601-607.

56

APPENDIX A

57

Table 2.1: ICD-9-CM codes for identification of cancer
ICD-9-CM code
Description
Malignant Neoplasm Of Lip, Oral Cavity, And
140.xx - 149.xx
Pharynx
Malignant Neoplasm Of Digestive Organs And
150.xx - 159.xx
Peritoneum
Malignant Neoplasm Of Respiratory And Intrathoracic
160.xx - 165.xx
Organs
Malignant Neoplasm Of Bone, Connective Tissue,
170.xx - 176.xx
Skin, And Breast
179.xx - 189.xx
Malignant Neoplasm Of Genitourinary Organs
190.xx - 199.xx
Malignant Neoplasm Of Other And Unspecified Sites
Malignant Neoplasm Of Lymphatic And
200.xx - 209.xx
Hematopoietic Tissue
230.xx - 234.xx
Carcinoma In Situ
235.xx - 238.xx
Neoplasms Of Uncertain Behavior
239.xx
Neoplasms Of Unspecified Nature
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Table 2.2: List of anti-Parkinson's drugs
Anti-Parkinson's drug class

Drug name
Benztropine
Biperiden
Diphenhydramine
Procyclidine
Trihexyphenidyl
Carbidopa
Carbidopa-Levodopa
Carbidopa/Entacapone/Levodopa
Levodopa
Entacapone
Tolcapone
Apomorphine
Bromocriptine
Cabergoline
Pergolide
Pramipexole
Ropinirole
Rotigotine
Rasagiline
Selegiline
Amantadine
Droxidopa
Pimavanersin
Rivastigmine Tartrate

Anticholinergic agents

Carbidopa/levodopa therapy agents

COMT inhibitors

Dopamine agonists

MAO-B inhibitors

Other parkinson's medications
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Table 2.3. Characteristics of PD cohort and non-PD cohort
Demographic and
All Subjects
PD Cohort
clinical
characteristics
(N = 11,130)
(N = 2,226)
Age in years, Mean
(SD)
Age Group (N, %)

Non-PD Cohort
(N = 8,904)

83.4

(7.3)

83.4

(7.3)

83.4

(7.3)

65-70

590

(5.3%)

118

(5.3%)

472

(5.3%)

71-75

1,198

(10.8%)

240

(10.8%)

958

(10.8%)

76-80

1,939

(17.4%)

387

(17.4%)

1,552

(17.4%)

81-85

2,648

(23.8%)

530

(23.8%)

2,118

(23.8%)

4,755

(42.7%)

951

(42.7%)

3,804

(42.7%)

5,855

(52.6%)

1,171

(52.6%)

4,684

(52.6%)

Female
Ethnicity (N, %)

5,275

(47.4%)

1,055

(47.4%)

4,220

(47.4%)

Caucasian

10,288

(92.4%)

2,102

(94.4%)

8,186

(91.9%)

540

(4.9%)

67

(3.0%)

473

(5.3%)

Other
Region (N, %)

302

(2.7%)

57

(2.6%)

245

(2.8%)

Northeast

1,973

(17.7%)

430

(19.3%)

1,543

(17.3%)

South

4,491

(40.4%)

846

(38.0%)

3,645

(40.9%)

Midwest

2,878

(25.9%)

586

(26.3%)

2,292

(25.7%)

West

1,755

(15.8%)

359

(16.1%)

1,396

(15.7%)

Other

33

(0.3%)

5

(0.2%)

28

(0.3%)

>85 years
Gender (N, %)
Male

African American
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Table 2.3 (Contd.). Characteristics of PD cohort and non-PD cohort
Demographic and
clinical
characteristics
CCI (Mean, SD)
CCI category

All Subjects
(N = 11,130)
3.4
(2.2)

PD Cohort

Non-PD Cohort

(N = 2,226)
3.4
(2.2)

(N = 8,904)
3.4
(2.2)

0

1,030

(9.3%)

206

(9.3%)

824

(9.3%)

1

1,445

(13.0%)

289

(13.0%)

1,156

(13.0%)

2

1,630

(14.6%)

326

(14.6%)

1,304

(14.6%)

3

1,845

(16.6%)

369

(16.6%)

1,476

(16.6%)

4+
5,180
Comorbidities of interest

(46.5%)

1,036

(46.5%)

4,144

(46.5%)

AZ

1,220

(11.0%)

364

(16.4%)

856

(9.6%)

Dementia

5,485

(49.3%)

1,672

(75.1%)

3,813

(42.8%)

Pneumonia

3,170

(28.5%)

695

(31.2%)

2,475

(27.8%)

Stroke

5,213

(46.8%)

1,243

(55.8%)

3,970

(44.6%)

CHF

5,674

(51.0%)

987

(44.3%)

4,687

(52.6%)
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Table 2.4. Comparison of 3-mon EOL All-Cause Healthcare Costs Between PD Cohort and non-PD Cohort
All
Direct Healthcare Costs 1
All-cause Costs
Total costs
Inpatient costs
Outpatient costs
Pharmacy costs
Palliative care costs

N = 11,130
$21,144
$13,753
$3,321
$808
$3,262

($24,066)
($21,507)
($3,978)
($2,158)
($4,515)

Adjusted cost 3 , mean (SE)
PD Cohort
Non-PD Cohort

Unadjusted cost, mean (SD)
PD Cohort
Non-PD Cohort
N = 2,226
$20,769
$12,206
$3,131
$886
$4,546

($20,555)
($18,671)
($3,494)
($1,850)
($4,977)

N = 8,904
$21,237
$14,139
$3,369
$788
$2,941

($24,866)
($22,143)
($4,089)
($2,229)
($4,333)

P-value 2
0.0006
0.0003
0.6884
<.0001
<.0001

N = 2,226
*
*
*
*

$24,248
$15,826
$3,677
$893
$3,892

($885)
($570)
($141)
($41)
($153)

N = 8,904
$23,978
$17,109
$3,722
$718
$2,859

($727)
($503)
($120)
($28)
($97)

P-value 3
0.7539
0.6137
0.5126
<.0001 *
<.0001 *

* P-value < 0.05

Table 2.5. Comparison of 9-mon EOL All-Cause Healthcare Costs Between PD Cohort and non-PD Cohort

Direct Healthcare Costs

All-cause Costs
Total costs
Inpatient costs
Outpatient costs
Pharmacy costs
Palliative care costs

N = 10,880

$40,960
$21,259
$6,351
$2,625
$6,785

($38,137)
($30,619)
($6,989)
($6,305)
($10,523)

N = 2,226

$45,701
$21,434
$6,554
$2,951
$9,583

($36,434)
($29,719)
($6,176)
($5,296)
($11,499)

N = 8,904

$39,775
$21,215
$6,301
$2,544
$6,085

($38,461)
($30,841)
($7,177)
($6,531)
($10,146)

P-value 2

<.0001
0.8746
<.0001
<.0001
<.0001

N = 2,226

*
*
*
*

$48,429
$26,125
$7,019
$3,108
$8,296

* P-value < 0.05
Healthcare costs were measured during the EOL period, defined as the 3-month period or 9-mon period prior to the index date
P-values were estimated from Wilcoxon rank-sum tests for comparison of unadjusted healthcare costs.

($1,369)
($913)
($232)
($129)
($358)

N = 8,904

$43,054
$25,684
$6,471
$2,444
$5,980

($1,090)
($745)
($179)
($86)
($223)
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All
1

Adjusted cost 3, mean (SE)
PD Cohort
Non-PD Cohort

Unadjusted cost, mean (SD)
PD Cohort
Non-PD Cohort

P-value 3

0.0324
0.0483
0.0009
<.0001
<.0001

*
*
*
*
*

Table 2.6. Generalized model assessing the relationship between PD and Allcause health care costs during the 3 mon EOL period
Beta Coefficient (95% CI, p)
Characteristic
Parkinson's Disease

All cause costs

P-value

0.01

-0.04

0.06

0.7539

0.16
0.12

0.07
-0.01

0.26
0.24

0.0005
0.0693

*

-0.11
-0.10
-0.02

-0.16
-0.16
-0.09

-0.05
-0.04
0.05

0.0002
0.001
0.5617

*
*

0.06
-0.07
0.26
0.33
0.52

-0.01
-0.12
0.22
0.29
0.48

0.13
-0.03
0.30
0.37
0.56

0.0732
0.001
<.0001
<.0001
<.0001

Race
African American
Other
Non-Hispanic White
(Ref)
Region
MW
W
S
NE (Ref)
Comorbidities
Alzheimer's Disease
Dementia
Pneumonia
Stroke
Congestive Heart Failure
* P-value < 0.05
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*
*
*
*

Table 7. Generalized model assessing the relationship between PD and Allcause health care costs during the 9 mon EOL period
Characteristic
Parkinson's Disease
Race
African American
Other
Non-Hispanic
White (Ref)
Region
MW
W
S
NE (Ref)
Comorbidities
Alzheimer's Disease
Dementia
Pneumonia
Stroke
Congestive Heart
Failure

Beta Coefficient (95% CI, p)
All cause costs
0.12
0.07
0.16

P-value
<.0001
*

0.0661
0.0054

-0.01
-0.10

0.15
0.11

0.1032
0.9206

-0.05
-0.06
0.03

-0.10
-0.11
-0.03

0.00
-0.01
0.09

0.0319
0.0174
0.2672

*
*

0.06
0.12
0.30
0.30
0.47

0.01
0.08
0.26
0.26
0.43

0.12
0.16
0.33
0.33
0.50

0.033
<.0001
<.0001
<.0001
<.0001

*
*
*
*
*

* P-value < 0.05
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Figure 2.1: Patient selection

Medicare patients who died between January 1, 2014 and December 31, 2016 were
identified and date of death is was considered as index date (N = 330,703)

Patients with at least two claims with ICD-9 diagnosis code 332.0 or ICD-10 diagnosis
code G20 in the one-year period prior to index date were defined as PD patients (N =
13,415)
2.
EOL period was determined using results from Joinpoint analysis and the six month period
prior to EOL period will be considered as baseline period

Patients should be at least 65 years of age as of January 1, 2014 and continuously enrolled
in Medicare Parts A, B & D throughout the study period and no managed care plans or
ESRD ( N = 3,241)

Patients without at least 1 claim with a diagnosis code for cancer during the study period
(N = 2,358)

Patients whose index date is between Apr 1, 2015 to December 31, 2016 (N = 2,226)

Patients without PD who died between Apr 1, 2015 to Dec 31, 2016 who met all inclusion and
exclusion criteria and were matched to PD cohort on age, sex and CCI (N = 8,904)
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CHAPTER 4: PAPER 3
End of Life Costs by Place at Death in Medicare Beneficiaries with Parkinson’s Disease:
An Instrumental Variable Approach
Introduction
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder
belonging to a group of conditions referred to as motor system disorders. The exact cause of PD
is unknown, but is attributed to the loss of neurons in the substantia nigra region of brain which
leads to reduced dopamine production (Samii, Nutt, & Ransom). As PD progresses, it affects a
person’s ability to control their movements and the overall body. Tremor, bradykinesia, rigidity
and postural instability are the primary motor symptoms of PD. Some of the non-motor symptoms
of PD include depression, apathy, sleep disorders and erectile dysfunction (Chaudhuri & Schapira,
2009; Jankovic, 2008). The course of PD usually starts with a diagnosis and maintenance phase
where complete symptom relief can be achieved with pharmacological treatment. It is followed by
a complex phase where motor complications and neuropsychiatric complications occur. This phase
is followed by a palliative phase where advanced PD is treated followed by the end of life (EOL)
care (Clarke, Sullivan, & Mason, 2006; Lokk & Delbari, 2012).
Palliative care is usually provided to patients during the EOL period. However, in the case
of PD treatment, palliative care is not necessarily equal to EOL care, since palliative care usually
starts before the EOL phase in patients who no longer respond to treatments. Palliative care is
initiated when patients are unable to tolerate dopaminergic therapy, unsuitable for surgery or when
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advanced comorbidities are present (Clarke et al., 2006; MacMahon & Thomas, 1998). The mean
duration of PD was estimated to be 14.6 years of which palliative care is usually provided for 2.2
years (MacMahon, Thomas, & Campbell, 1999). In the initial phases of PD such as diagnosis and
maintenance phase, PD symptoms improve with the use of medication. As the disease progresses,
PD symptoms do not improve with medication therapy and a high percentage of patients (~30%)
experience symptoms such as depression, hallucinations and falls. These symptoms often lead the
PD patients to seek institutional palliative care (Lökk, 2008). Institutional palliative care is
provided in long term care (LTC) facilities, skilled nursing facilities (SNF) or freestanding Hospice
facilities. Institutional palliative care usually aims to prevent further complications and provide
symptom relief (Thomas & MacMahon, 2004).
While institutional palliative care is frequently used during the EOL period with around
60% of deaths happening in hospital, some patients prefer to die at home (Gallup, 1997; Hays,
Galanos, Palmer, McQuoid, & Flint, 2001; Weitzen, Teno, Fennell, & Mor, 2003). Such patients
are provided care through Home Health agencies and home-based Hospice services. While
hospital-based EOL care has shown to improve some aspects of quality of life in patients during
the EOL period, there is evidence of favorable dying experience at home when compared to an
institutional setting (Higginson et al., 2002; Teno et al., 2004). Previous studies have shown that
the use of home-based care with a multidisciplinary approach consisting of symptom control, pain
relief, emotional and spiritual support and patient education resulted in a significantly lower
healthcare resource use, costs and better quality of life when compared to other home-based care
services such as home health care, home-based hospice care or institutional palliative care services
such as hospice care during the EOL period (R. Brumley et al., 2007; R. D. Brumley, Enguidanos,
& Cherin, 2003; Lustbader et al., 2017). For example, in a randomized trial conducted in terminally
68

ill patients, Brumley et al., (2007) found that when compared to patients receiving usual care such
as Home Health services, acute care services, primary care services, and Hospice care, patients
enrolled in an interdisciplinary home-based care program during the EOL period had higher patient
satisfaction and lower healthcare resource use. EOL costs place a disproportionate burden on
Medicare with around 30% of yearly spending on 5% to 6% patients that die in that year (Emanuel
& Emanuel, 1994). EOL costs calculated in previous studies may not be representative of the EOL
costs in PD patients since a significant percentage of patients receiving EOL care are cancer
patients (Duncan, Ahmed, Dove, & Maxwell, 2019; Hogan, Lunney, Gabel, & Lynn, 2001).
Considering the high burden of EOL costs on Medicare, it is essential to understand the EOL costs
in PD patients enrolled in Medicare and to assess the impact of place at death on EOL costs. Results
from such a study will complement studies on quality of life improvement and dying experience
during the EOL period to aid discussions regarding patient’s choice of EOL care. In this study, we
aim to understand the association between place at death and EOL costs among older Medicare
beneficiaries with PD. An instrumental variable (IV) was used to control for confounding and
measurement error in this study.
In retrospective observational studies using claims database, patients cannot be randomly
allocated to interventions such as use of Home-based palliative care or institutional palliative care.
The choice of place of palliative care during the EOL period depends on a number of factors such
as the severity of patient’s disease and patient’s preference for palliative care. The availability of
palliative care services in the patient’s region may also play an important role in patient’s choice
of the place of palliative care. In addition, physician recommendations may also influence patient’s
choice. Lack of randomization can lead to treatment selection bias in a study. Use of multivariable
models can control for observed differences between patients in treatment groups but are unable
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to minimize the unmeasured confounding due to strong selection bias (Stukel et al., 2007). IV
analysis is an econometric method which can be used to control for confounding in observational
studies when randomization is not feasible. An IV can be considered as a variable which can
introduce variation in the exposure (place at death) variable like a randomized assignment. An IV
can adjust for both observed and unobserved confounding and should have two key characteristics
1) it is highly associated with the patient’s choice of place of receiving EOL care and 2) the
instrument does not independently affect the outcome, which is EOL costs in the study (Brookhart,
Rassen, & Schneeweiss, 2010; Newhouse & McClellan, 1998). Since the IV is highly associated
with intervention, the variation in IV induces a variation called exogenous variation in the
intervention variable which mimics randomization. While ordinary least squares (OLS) regression
measures the effect of intervention on the outcome, IV regression measures the effect of exogenous
variation in the intervention on the outcome. Thus, the use of IV regression can lead to unbiased
estimation of the relationship between intervention (place at death) and the outcome (EOL cost)
(Earle et al., 2001; Newhouse & McClellan, 1998; Penrod, Goldstein, & Deb, 2009; Stukel et al.,
2007).
Methods
Data Source and Study Design
A retrospective observational cohort study was conducted using data from Medicare 5% random
national sample claims from January 1, 2014 – December 31, 2016 which is made available
through the Centers for Medicare and Medicaid services (CMS) for research purposes. This
database contains the claims of healthcare services offered to Medicare beneficiaries including
inpatient, outpatient, long-term care, skilled nursing facility (SNF), Hospice, Home Health and
prescription drugs. The Medicare Beneficiary Summary file contains information related to
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patients’ demographics, enrollment status and mortality information. The Medicare Carrier file
contained claims related to services provided by non-institutional providers such as physicians,
nurse practitioners and physician assistants. Outpatient file contained claims related to services
performed by institutional outpatient providers like hospitals, renal dialysis facilities and
community mental health centers etc. Inpatient and SNF services claims were provided in the
MedPAR files. Services provided through Home Health agencies were provided in the Home
Health Agency (HHA) research identifiable files (RIF). Hospice RIF contained the fee for service
and managed care claims submitted by Hospice providers once the beneficiaries have opted for
Hospice services. These files contain procedure codes of services which were classified using the
Current Procedural Terminology (CPT) along with ICD-9/ ICD-10 diagnosis codes and the amount
reimbursed for the services. Records for prescription drugs dispensed under Medicare part D were
included in the Part D Drug Event (PDE) file. An encrypted beneficiary identification number is
used to link the claims. This study was approved by the Institutional Review Board (IRB) of the
University of Mississippi.
Patient Selection
The sample for this study contained Medicare beneficiaries who: (1) were ≥ 65 years of
age as of January 1, 2014 (2) who died during the period between April 1, 2015 to December 31,
2016 (3) who had continuous enrollment in Medicare Parts A, B, & D from January 1, 2014 to
index date. Only Patients who received home-based palliative care and died at home or patients
who received institutional palliative care and died at a medical facility were included in the study.
In the current study, the identification of Medicare beneficiaries with PD was based on the
approach outlined by Szumski et al. (2009). Patients with at least two medical claims containing
ICD-9 diagnosis code 332.0 or ICD-10 diagnosis code G20 in the one-year period prior to index
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date will be defined as PD patients. This approach to identify PD was found to have a sensitivity
of 89.2% and a positive predictive value (PPV) of 79.4% (Szumski & Cheng, 2009). The date of
death was identified from the Medicare Beneficiary Summary file and was considered as the index
date. The duration of EOL period was determined as the 9-mon period prior to death using results
from the Joinpoint analysis. Sensitivity analysis was performed by varying the definition of EOL
period as 3 months prior to death. The six month period prior to EOL period was considered as
baseline period. Dual eligible beneficiaries, patients enrolled in managed care, patients with
unknown location of death (identified using patient discharge status code 42 from Hospice RIF or
MedPAR RIF), patients with end stage renal disease (ESRD) or cancer (ICD-9-CM/ICD-10 codes
presented in Table 1) during the study period were excluded. A diagrammatic representation of
patient selection is provided in Figure 1.
Measures
Outcome Variable
The outcome measured in the study was all-cause healthcare costs. Costs were measured
during the EOL period and were adjusted to 2016 USD using the medical component of consumer
price index (CPI). This study was conducted from Medicare’s perspective therefore payments
made by patients such as co-payments and deductibles were not included in the cost calculation.
All-cause healthcare costs included payments made for outpatient services, office visits,
emergency department (ED) visits, inpatient services, SNF/LTC services, Home Health services,
Hospice services and prescription drug costs.
Exposure Variable
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The key exposure variable of interest was the place at death. PD patients were categorized
as “died at institutional hospice” or “died at non-institutional hospice”. Place at death was
identified using the patient discharge status variable “PTNT_DSCHRG_STUS_TB” in Hospice
RIF and “STUS_CD” in Home Health RIF. Patients with discharge status “41” and who had at
least one claim for hospice during the 90-day period prior to death were included in hospice cohort.
Patients with discharge status “40” who did not have at least one hospice claim were included in
non-hospice cohort.
Covariates
Covariates in the study included age, gender, race, modified Charlson Comorbidity Index
(CCI), geographic region and PD severity. Age was calculated at index date and was used as a
continuous variable. Gender was measured as male or female. Race was categorized as nonHispanic white, African American, Hispanics and other racial group (including Asian, Native
Hawaiian, Pacific Islander, American Indian or Alaskan Native, or unknown race). Geographic
region was categorized as Northeast, South, Midwest and West. Deyo adaptation of CCI was
modified by excluding diagnosis codes for cancer and metastases. Modified CCI was calculated
during the baseline period using ICD-9/ICD-10 diagnosis codes from MedPAR, Carrier and
Outpatient files (Deyo, Cherkin, & Ciol, 1992). The mean daily load of PD medication was used
as a proxy measure for PD severity. A previous study found that the mean daily tablet load of early
PD patients is 3.2 tablets of PD-related medications. In advanced PD patients the mean daily tablet
load ranged from 8.4 to 9.9 tablets of PD-related medications (Fargel, Grobe, Oesterle, Hastedt, &
Rupp, 2007). Hence patients with a mean daily PD-related tablet load of more than 8, 4 to 7, 3 and
less were categorized as advanced PD patients, mid stage PD patients and early PD patients
respectively. The mean daily PD-related tablet load was calculated during the baseline period. In
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addition, a number of comorbidities of interest, including Alzheimer’s disease, dementia,
pneumonia, stroke and congestive heart failure (CHF) during the baseline period were included as
covariates.
Instrumental Variables (IV)
Due to the observational nature of the study design it is not feasible to randomly assign
patients to home-based palliative care or institutional palliative care. To minimize the bias due to
lack of randomization, an instrumental variable (IV) approach was used to account for observed
and unobserved confounding biases. (Carlsen & Grytten, 1998; D’Agostino, 2007; Newhouse &
McClellan, 1998; Stukel et al., 2007).
The instruments used in this study were identified in calendar year 2016. Three instruments
were used in the study: the first instrument (IV1) was based on the regional variation at the Health
Service Area (HSA) level in the use of EOL care among all PD patients. It is the ratio of the number
PD patient’s receiving EOL care at home to the number of PD patient’s receiving EOL care at an
institutional facility. The rationale for using an instrument based on regional variation in the use
of EOL care is that a patient’s preference for EOL care is more likely to be influenced by the wide
spread use of a particular EOL service in that geographic unit (Basu, Heckman, Navarro‐Lozano,
& Urzua, 2007; Stukel et al., 2007). The second instrument (IV2) was based on physician
preference of home-based palliative care versus institutional palliative care in PD patients. The
rationale for using this instrument is that physician recommendations play an important role in
patient’s choice of EOL care (Brookhart et al., 2010; Brookhart, Wang, Solomon, & Schneeweiss,
2006; Wang et al., 2005). All PD patients who met study inclusion and exclusion criteria were
assigned a primary physician, defined as the physician who wrote the highest number of PD
prescriptions during the EOL period or the physician who had the highest number of
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outpatient/office visits for the treatment of PD during the EOL period. The ratio of patients who
used home-based palliative care to total number of patients was calculated for each of these
designated primary physicians during 2016 and used as an IV for physician preference in the study.
The third instrument (IV3) was based on the availability of home-based palliative care providers
such as Home Health agencies and institutional palliative care providers such as freestanding
Hospice agencies in the patient’s HSA. The ratio of the number of Home Health agencies to the
total number of Home Health agencies and free standing Hospice agencies was used as the third
IV. The rationale for using this instrument is that patients are likely to choose the type of EOL care
based on the availability of the services. Also, the availability of EOL care in a particular region
can also lead to physician enthusiasm or supplier induced demand (Carlsen & Grytten, 1998;
Pritchard et al., 1998).
Statistical Analysis
Descriptive characteristics for the non-hospice cohort and hospice cohort were reported
using means and standard deviations (SD) for continuous variables and frequencies and
percentages for categorical variables. T-tests and chi-squared tests were used to compare
continuous variables and categorical variables respectively. In the IV analysis, relevance of
instruments was tested using first-stage regressions and Durbin-Wu-Hausman test was used to test
the endogeneity in IV estimation. The impact of place at death on EOL costs was assessed using a
two stage least squares regression (2SLS) controlling for baseline characteristics including age,
gender, race, modified CCI, geographic region and PD severity. Costs were log-transformed and
a two stage least squares regression using the PROC SYSLIN procedure in SAS (SAS Institute
Inc., Cary, NC) was used to conduct the IV analysis.
Results
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A total of 1,354 older PD patients who died during the index period (Apr 1, 2015 to Dec
31, 2016) met our inclusion criteria. Of these, 749 patients used home-based palliative care
services during the 90-day period prior to death and died at home were included in the non-hospice
cohort. A total of 605 patients who used institutional palliative care during the 90-day period prior
to death and died at an institutional facility providing palliative care were included in the hospice
cohort. Demographic and clinical characteristics of patients in both cohorts were presented in
Table 2. The mean age of patients in the overall study sample was 83.9 (±7.1) with around 45% of
patients in the age group > 85 years. Patients in non-hospice cohort were slightly older when
compared to the hospice cohort (mean age of 84.6 in non-hospice cohort vs 83.4 in hospice cohort,
p = 0.006). Around 94% of patients in overall study sample were non-Hispanic whites. Average
comorbidity burden, as measured by CCI, was significantly higher in patients who used
institutional palliative care (3.1 in non-hospice cohort vs. 3.5 in hospice cohort, p = 0.0002).
Around 40.9% of patients in the non-hospice cohort had CCI score ≥ 4 when compared to 47.9%
in hospice cohort (p = 0.002). Also, the prevalence of comorbidities of interest, such as
Alzheimer’s disease, dementia, pneumonia, stroke and CHF during the baseline period was
significantly higher in the hospice cohort when compared to the non-hospice cohort.
Mean unadjusted all-cause costs during the 9-month EOL period were significantly lower
in non-hospice cohort when compared to the hospice cohort [$47,316 (± 32,095) vs. $53,581 (±
$35,128), p = 0.0001]. EOL costs were largely driven by hospitalization costs in both cohorts with
inpatient services contributing to more than 35% EOL costs. Mean costs incurred towards
inpatient, outpatient/office visits, pharmacy costs were higher in hospice cohort when compared
to non-hospice cohort. However, the average costs incurred towards palliative care services were
higher in non-hospice cohort [$15,105 (± $12,902) vs. $11,526 (± $11,439) in hospice cohort, p <
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0.0001]. The distribution of components of all-cause costs 9-month EOL period were provided in
Table 4. In the sensitivity analysis using 3 months prior to death as EOL, similar trends were
observed (Table 3). During the 3-month EOL period, all-cause costs in non-hospice cohort were
significantly lower than hospice cohort [$18,530 (± $ 16,457) vs. $21,912 (± 18,675), p < 0.0001].
The effect of the choice of EOL care and EOL costs were examined using a conventional
OLS model controlling for observed confounding, and an IV model controlling for observed and
unobserved confounding. IVs under consideration were tested for exogeneity to ensure that they
explain the variation in the exposure variable. First the correlation between all the three IVs and
the exposure variable (choice of EOL care) was assessed (Table 5). IV2 (physician preference)
and IV3 (availability of EOL care) were significantly correlated with choice of EOL care, but IV1
(patient preference) was not significantly correlated with the choice of EOL care. While IV1 was
not significantly correlated with choice of EOL care, it was still included in the model since IV1
may be able to explain the variation in choice of EOL care given other covariates in the model and
there is strong theoretical basis that patient preferences are significantly related to EOL decisions.
Hausman test for endogeneity was found to be significant at an alpha level of 0.05 when IVs 1 and
3 were used together (t=2.47; p=0.014), which provides evidence to suggest that the IVs are
exogenous and the IV model is more efficient than the conventional OLS model (Tables 6 and 7).
A comparison of results for the association between 3-mon and 9-mon EOL costs and
choice of EOL care from the OLS model and IV model were presented in Tables 8 and 9
respectively. Based on the conventional OLS model, after controlling for all covariates, patients
using home-based palliative care were found to be associated with significantly lower EOL costs
when compared to patients using institutional palliative care (β = -0.07, p = 0.036). In contrast, IV
model has shown that patients using home-based palliative care were associated with higher costs
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when compared to patients using institutional palliative care. However, this relationship in IV
model was not statistically significant (β = 0.24, p = 0.431).
Discussion
In this study, we assessed the impact of the choice of EOL care and all-cause healthcare
costs during EOL period among older Medicare patients with PD using an IV approach. While
previous studies found that patients with non-cancer conditions and patients in general are more
likely to use hospice care during EOL period (Duncan et al., 2019; Stevenson, Huskamp,
Grabowski, & Keating, 2007), results from our study suggest that the use of non-hospice care is
higher in PD patients when compared to hospice care. These results also indicate that patients with
higher comorbidity burden were more likely to choose hospice care during EOL period. We also
found that unadjusted all-cause costs were significantly higher in patients who used hospice care
cohort when compared to patients who were in non-hospice cohort. A previous study by Duncan
et al. (2019) in a general sample of Medicare patients estimated per patient per month (PPPM)
palliative care costs to be $2,336 in patients who died in Hospice and $1,104 in patients who died
in Home Health setting (Duncan et al., 2019). These results are in contrast with our study which
found that palliative care costs in PD patients is higher among patients in non-hospice cohort when
compared to patients in hospice cohort. The lower costs in non-hospice cohort in Duncan et al.
(2009) study could be due to the lower sample size of patients who died while using home health
services or could be due to inclusion of patients with primary cancers who were more likely to use
institutional care during EOL periods (Addington-Hall, Altmann, & McCarthy, 1998). Change in
intent of treatment to non-curative treatment during the last few months before death is associated
with less aggressive treatments in PD patients (Gozalo, Plotzke, Mor, Miller, & Teno, 2015).
While this change in treatment approach may reduce the cost of treatment, these reduced costs due
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to less aggressive treatments were offset by higher costs incurred towards EOL care leading to
higher EOL costs in PD patients when compared to patients without PD.
Our study used both conventional OLS regression and IV regression to assess the
relationship between choice of EOL care and EOL costs. Results from conventional OLS
regression indicate that all-cause costs in the non-hospice cohort were significantly lower than
hospice cohort. However, there are several unobserved confounders which might influence the
patient’s choice of EOL care. Factors such as desire to stay in the proximity of family, having care
givers, ability to perform activities of daily living, patient’s quality of life all play an important
role in patient’s EOL care decisions. While randomization can be a way to minimize such
unobserved confounding, it is not feasible in observational studies using retrospective claims
databases. Hence, our study used an instrumental variable approach which can theoretically
account for both observed and unobserved confounding due to the choice of end of life care to
provide a better estimate of the impact of choice of EOL care and EOL costs. Results from IV
model suggest that EOL costs were higher in the non-hospice cohort but the results did not reach
statistical significance. These findings have practical significance for several reasons. First, the
type of care desired by the patients may be associated with lower costs, thus health care systems
should focus on providing better access to home-based EOL care. While institutional care in
general is associated with higher Medicare expenditures (Gozalo et al., 2015), our findings indicate
that EOL costs are not significantly different between home-based versus institutional care among
older PD patients once we account for both the observed and unobserved confounding.
Our choices of the three IVs needs further discussion. The first IV was patient’s preference
of EOL care in a geographic region. While this patient preference IV was not significantly
correlated with the choice of EOL care, we nevertheless included it as an IV due to the strong
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theoretical basis for patient preference in choosing EOL care (Barnato et al., 2007; Gramelspacher,
Zhou, Hanna, & Tierney, 1997; Hofmann et al., 1997). Also, the use of patient preferences,
physician preferences along with availability of EOL care services at a HSA level can minimize
the possibility of instrument-outcome confounding (Garabedian, Chu, Toh, Zaslavsky, &
Soumerai, 2014).
The second IV was physician’s choice in EOL care. We first identified the physician
associated with PD treatment as patient’s primary prescriber of the patient. We then assessed the
percentage of patients treated by the prescriber who are using home-based care to all patients using
home-based or institutional palliative care as an IV. However, considering the stage of PD, some
patients may not be prescribed any PD-related medications but we assigned the physician
associated with most PD diagnoses as the patient’s primary prescriber. This physician preference
IV was significantly correlated with EOL care choice. However, inconsistent with previous
studies, based on Hausman test for endogeneity, we found that it was not a significant IV. This
inconsistency could be due to the nature of our research question in answering which we used
physician preference as an IV for patient’s choice in EOL care locations while previous studies
used physician preference as IVs for actual treatment selection (Brookhart et al., 2006; Rassen,
Brookhart, Glynn, Mittleman, & Schneeweiss, 2009). While physicians are often the one to initiate
EOL conversations with patients, it is unclear whether the patient’s EOL care decisions were more
influenced by the physician treating PD or their primary care physicians (PCP) (Ionescu-Ittu,
Abrahamowicz, & Pilote, 2012; Markson et al., 1997; Ramanayake, Dilanka, & Premasiri, 2016;
Sachs, Shega, & Cox-Hayley, 2004). Further research is necessary into determining the role played
by PCP’s and specialists on EOL care decisions of patients.
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In order to assess the third IV, the availability of EOL care in the patient’s geographic
location (HSA), our study used the list of providers who were registered with CMS for providing
home-based and institutional EOL care to Medicare patients. EOL care availability was
significantly correlated with patients’ EOL choice and this IV was also found to be valid based on
Hausman test. While there is a chance of Medicare patients using non-registered EOL care
providers, there is less likelihood since the requirements to register with CMS are not stringent
Also, our study did not account for the newer programs instituted by CMS such as Medicare Care
Choices Model which is designed to increase access to hospice care and could be associated with
better payments based on quality of care (Medicare & Services, 2016). However, considering that
this program was started towards the end of 2015 in very few centers, the impact of these programs
on patient’s EOL care choice during our study period could be minimal.
Our study results must be interpreted in light of certain limitations. Patients who died at
home and did not use hospice services in the 90-day period were included in the non-hospice
cohort and a similar approach was used to identify patients in the hospice cohort. However, we
cannot establish with certainty that the patient truly used only hospice services or non-hospice
services. Our study did not include patients who used hospice or home health services and died at
an inpatient setting. In order to minimize the possible misclassification, we categorized patients
into hospice and non-hospice cohorts based on use of the EOL services during the 90-day period
prior to death along with the discharge code indicating the place of death. While the impact of
place of death on EOL costs was assessed in our study, we did not assess the impact of type of
EOL care used on costs during EOL period. Also, intent of treatment can be a significant predictor
of EOL costs (Näppä, Lindqvist, Rasmussen, & Axelsson, 2011; Zdenkowski, Cavenagh, Ku,
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Bisquera, & Bonaventura, 2013). However, we cannot accurately ascertain intent of treatment
from Medicare claims data.
Our study has several strengths. First, we used retrospective data from the 5% national
Medicare sample which contains administrative claims for patients from all the states in the US.
In addition to the data’s geographic representation, considering that PD is more prevalent in
patients more than 65 years of age, Medicare database is the most appropriate database to assess
the impact of home-based versus institution care and EOL care cost in older PD patients. Second,
Medicare data contains patient’s death information through social security administration which
is accurate and thus enables better estimation of EOL costs when compared to the use of proxy
algorithms. For example, due to patient privacy issues, commercial claims databases do not
provide information on death and studies using these databases rely on proxy algorithms which
consider loss of enrollment for pharmacy and medical benefits shortly after a life threatening event
to identify death (Joyce et al., 2004). In addition, patients in Medicare FFS or Medicare advantage
plans have coverage for palliative care services provided by Home Health or Hospice agencies,
patients in commercial insurance plans have limited coverage (Chung, Jahng, Petrosyan, Kim, &
Yim, 2015; Jackson, Gibson, & Staeheli, 2000). Moreover, the use of Medicare data also provides
an opportunity to estimate the real-world costs associated with EOL care in PD patients managed
in real-world care settings.
Conclusion
In summary, among older Medicare PD patients who died, all-cause EOL costs were
significantly lower in the non-hospice cohort as compared to those in the institutional care cohort
using conventional OLS model controlling for the effects of observed confounding only. After
controlling for the effect of unobserved confounders with an IV approach, we found that all-cause
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EOL costs among patients in the non-hospice cohort were not significantly different from patients
in the hospice cohort. However, choice of EOL care among PD patients should be a joint decision
between patients and healthcare providers; patient preferences and patient quality of life during
EOL period should be considered to design novel EOL care programs which can reduce costs and
improve patient’s EOL care experience.

83

BIBLIOGRAPHY

84

Addington-Hall, J., Altmann, D., & McCarthy, M. (1998). Which terminally ill cancer patients
receive hospice in-patient care? Social Science & Medicine, 46(8), 1011-1016.
Barnato, A. E., Herndon, M. B., Anthony, D. L., Gallagher, P. M., Skinner, J. S., Bynum, J. P., &
Fisher, E. S. (2007). Are regional variations in end-of-life care intensity explained by
patient preferences?: A Study of the US Medicare Population. Medical care, 45(5), 386.
Basu, A., Heckman, J. J., Navarro‐Lozano, S., & Urzua, S. (2007). Use of instrumental variables
in the presence of heterogeneity and self‐selection: An application to treatments of breast
cancer patients. Health Economics, 16(11), 1133-1157.
Brookhart, M. A., Rassen, J. A., & Schneeweiss, S. (2010). Instrumental variable methods in
comparative safety and effectiveness research. Pharmacoepidemiology and drug safety,
19(6), 537-554.
Brookhart, M. A., Wang, P., Solomon, D. H., & Schneeweiss, S. (2006). Evaluating short-term
drug effects using a physician-specific prescribing preference as an instrumental variable.
Epidemiology (Cambridge, Mass.), 17(3), 268.
Brumley, R., Enguidanos, S., Jamison, P., Seitz, R., Morgenstern, N., Saito, S., . . . Gonzalez, J.
(2007). Increased satisfaction with care and lower costs: results of a randomized trial of
in‐home palliative care. Journal of the American Geriatrics Society, 55(7), 993-1000.
Brumley, R. D., Enguidanos, S., & Cherin, D. A. (2003). Effectiveness of a home-based
palliative care program for end-of-life. Journal of palliative medicine, 6(5), 715-724.
Carlsen, F., & Grytten, J. (1998). More physicians: improved availability or induced demand?
Health Economics, 7(6), 495-508.
Chaudhuri, K. R., & Schapira, A. H. (2009). Non-motor symptoms of Parkinson's disease:
dopaminergic pathophysiology and treatment. The Lancet Neurology, 8(5), 464-474.
Chung, K., Jahng, J., Petrosyan, S., Kim, S. I., & Yim, V. (2015). Assessment of levels of
hospice care coverage offered to commercial managed care plan members in California:
implications for the California Health Insurance Exchange. American Journal of Hospice
and Palliative Medicine®, 32(4), 440-447.
Clarke, C., Sullivan, T., & Mason, A. (2006). National clinical guideline for diagnosis and
management in primary and secondary care. National Collaborating Centre for Chronic
Conditions Parkinson’s disease.
D’Agostino, R. B. (2007). Estimating treatment effects using observational data. Jama, 297(3),
314-316.
Deyo, R. A., Cherkin, D. C., & Ciol, M. A. (1992). Adapting a clinical comorbidity index for use
with ICD-9-CM administrative databases. Journal of clinical epidemiology, 45(6), 613619.
Duncan, I., Ahmed, T., Dove, H., & Maxwell, T. L. (2019). Medicare Cost at End of Life.
American Journal of Hospice and Palliative Medicine®, 1049909119836204.
Earle, C. C., Tsai, J. S., Gelber, R. D., Weinstein, M. C., Neumann, P. J., & Weeks, J. C. (2001).
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental
variable and propensity analysis. Journal of clinical oncology, 19(4), 1064-1070.

85

Emanuel, E. J., & Emanuel, L. L. (1994). The economics of dying--the illusion of cost savings at
the end of life. New England Journal of Medicine, 330(8), 540-544.
Fargel, M., Grobe, B., Oesterle, E., Hastedt, C., & Rupp, M. (2007). Treatment of Parkinson's
disease: a survey of patients and neurologists. Clinical drug investigation, 27(3), 207219.
Gallup, G. (1997). Spiritual beliefs and the dying process: a report on a national survey.
Conducted for the Nathan Cummings Foundation and the Fetzer Institute.
Garabedian, L. F., Chu, P., Toh, S., Zaslavsky, A. M., & Soumerai, S. B. (2014). Potential bias
of instrumental variable analyses for observational comparative effectiveness research.
Annals of internal medicine, 161(2), 131-138.
Gozalo, P., Plotzke, M., Mor, V., Miller, S. C., & Teno, J. M. (2015). Changes in Medicare costs
with the growth of hospice care in nursing homes. New England Journal of Medicine,
372(19), 1823-1831.
Gramelspacher, G. P., Zhou, X. H., Hanna, M. P., & Tierney, W. M. (1997). Preferences of
physicians and their patients for end‐of‐life care. Journal of general internal medicine,
12(6), 346-351.
Hays, J. C., Galanos, A. N., Palmer, T. A., McQuoid, D. R., & Flint, E. P. (2001). Preference for
place of death in a continuing care retirement community. The Gerontologist, 41(1), 123128.
Higginson, I. J., Finlay, I., Goodwin, D. M., Cook, A. M., Hood, K., Edwards, A. G., . . .
Norman, C. E. (2002). Do hospital-based palliative teams improve care for patients or
families at the end of life? Journal of pain and symptom management, 23(2), 96-106.
Hofmann, J. C., Wenger, N. S., Davis, R. B., Teno, J., Connors, A. F., Desbiens, N., . . . Phillips,
R. S. (1997). Patient preferences for communication with physicians about end-of-life
decisions. Annals of internal medicine, 127(1), 1-12.
Hogan, C., Lunney, J., Gabel, J., & Lynn, J. (2001). Medicare beneficiaries’ costs of care in the
last year of life. Health affairs, 20(4), 188-195.
Ionescu-Ittu, R., Abrahamowicz, M., & Pilote, L. (2012). Treatment effect estimates varied
depending on the definition of the provider prescribing preference-based instrumental
variables. Journal of clinical epidemiology, 65(2), 155-162.
Jackson, B., Gibson, T., & Staeheli, J. (2000). Hospice benefits and utilization in the large
employer market. The Medstat Group.
Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology,
Neurosurgery & Psychiatry, 79(4), 368-376.
Joyce, A. T., Iacoviello, J. M., Nag, S., Sajjan, S., Jilinskaia, E., Throop, D., . . . Alexander, C.
M. (2004). End-stage renal disease-associated managed care costs among patients with
and without diabetes. Diabetes Care, 27(12), 2829-2835.
Lökk, J. (2008). Caregiver strain in Parkinson's disease and the impact of disease duration.
European Journal of Physical and Rehabilitation Medicine, 44(1), 39-45.
Lokk, J., & Delbari, A. (2012). Clinical aspects of palliative care in advanced Parkinson’s
disease. BMC palliative care, 11(1), 20.
Lustbader, D., Mudra, M., Romano, C., Lukoski, E., Chang, A., Mittelberger, J., . . . Cooper, D.
(2017). The impact of a home-based palliative care program in an accountable care
organization. Journal of palliative medicine, 20(1), 23-28.
MacMahon, D., & Thomas, S. (1998). Practical approach to quality of life in Parkinson’s
disease: the nurse’s role. Journal of neurology, 245, S19-S22.
86

MacMahon, D., Thomas, S., & Campbell, S. (1999). Validation of pathways paradigm for the
management of PD. Parkinsonism & related disorders, 5.
Markson, L., Clark, J., Glantz, L., Lamberton, V., Kern, D., & Stollerman, G. (1997). The
doctor's role in discussing advance preferences for end‐of‐life care: Perceptions of
physicians practicing in the VA. Journal of the American Geriatrics Society, 45(4), 399406.
Medicare, C. f., & Services, M. (2016). Medicare care choices model.
Näppä, U., Lindqvist, O., Rasmussen, B., & Axelsson, B. (2011). Palliative chemotherapy during
the last month of life. Annals of oncology, 22(11), 2375-2380.
Newhouse, J. P., & McClellan, M. (1998). Econometrics in outcomes research: the use of
instrumental variables. Annual review of public health, 19(1), 17-34.
Penrod, J. D., Goldstein, N. E., & Deb, P. (2009). When and how to use instrumental variables in
palliative care research. Journal of palliative medicine, 12(5), 471-474.
Pritchard, R. S., Fisher, E. S., Teno, J. M., Sharp, S. M., Reding, D. J., Knaus, W. A., . . . Lynn,
J. (1998). Influence of patient preferences and local health system characteristics on the
place of death. Journal of the American Geriatrics Society, 46(10), 1242-1250.
Ramanayake, R., Dilanka, G., & Premasiri, L. (2016). Palliative care; role of family physicians.
Journal of family medicine and primary care, 5(2), 234.
Rassen, J. A., Brookhart, M. A., Glynn, R. J., Mittleman, M. A., & Schneeweiss, S. (2009).
Instrumental variables II: instrumental variable application—in 25 variations, the
physician prescribing preference generally was strong and reduced covariate imbalance.
Journal of clinical epidemiology, 62(12), 1233-1241.
Sachs, G. A., Shega, J. W., & Cox-Hayley, D. (2004). Barriers to excellent end-of-life care for
patients with dementia. Journal of general internal medicine, 19(10), 1057-1063.
Samii, A., Nutt, J. G., & Ransom, B. R. Parkinson's disease. The Lancet, 363(9423), 1783-1793.
doi:10.1016/S0140-6736(04)16305-8
Stevenson, D. G., Huskamp, H. A., Grabowski, D. C., & Keating, N. L. (2007). Differences in
hospice care between home and institutional settings. Journal of palliative medicine,
10(5), 1040-1047.
Stukel, T. A., Fisher, E. S., Wennberg, D. E., Alter, D. A., Gottlieb, D. J., & Vermeulen, M. J.
(2007). Analysis of observational studies in the presence of treatment selection bias:
effects of invasive cardiac management on AMI survival using propensity score and
instrumental variable methods. Jama, 297(3), 278-285.
Szumski, N. R., & Cheng, E. M. (2009). Optimizing algorithms to identify Parkinson's disease
cases within an administrative database. Movement Disorders, 24(1), 51-56.
Teno, J. M., Clarridge, B. R., Casey, V., Welch, L. C., Wetle, T., Shield, R., & Mor, V. (2004).
Family perspectives on end-of-life care at the last place of care. Jama, 291(1), 88-93.
Thomas, S., & MacMahon, D. (2004). Parkinson’s disease, palliative care and older people: Part
1. Nursing older people, 16(2), 22-26.
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., &
Brookhart, M. A. (2005). Risk of death in elderly users of conventional vs. atypical
antipsychotic medications. New England Journal of Medicine, 353(22), 2335-2341.
Weitzen, S., Teno, J. M., Fennell, M., & Mor, V. (2003). Factors associated with site of death: a
national study of where people die. Medical Care, 41(2), 323-335.

87

Zdenkowski, N., Cavenagh, J., Ku, Y., Bisquera, A., & Bonaventura, A. (2013). Administration
of chemotherapy with palliative intent in the last 30 days of life: the balance between
palliation and chemotherapy. Internal medicine journal, 43(11), 1191-1198.

88

APPENDIX A

89

Table 3.1: ICD-9-CM codes for identification of cancer
ICD-9-CM code
Description
Malignant Neoplasm Of Lip, Oral Cavity, And
140.xx - 149.xx
Pharynx
Malignant Neoplasm Of Digestive Organs And
150.xx - 159.xx
Peritoneum
Malignant Neoplasm Of Respiratory And Intrathoracic
160.xx - 165.xx
Organs
Malignant Neoplasm Of Bone, Connective Tissue,
170.xx - 176.xx
Skin, And Breast
179.xx - 189.xx
Malignant Neoplasm Of Genitourinary Organs
190.xx - 199.xx
Malignant Neoplasm Of Other And Unspecified Sites
Malignant Neoplasm Of Lymphatic And
200.xx - 209.xx
Hematopoietic Tissue
230.xx - 234.xx
Carcinoma In Situ
235.xx - 238.xx
Neoplasms Of Uncertain Behavior
239.xx
Neoplasms Of Unspecified Nature
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Table 3.2. Characteristics of patients in the non-Hospice Cohort and Hospice
Cohort
Institutional
Non- hospice
Demographic and
All Patients
hospice cohort
cohort patients
clinical
patients
characteristics
(N = 1,354)
(N = 749)
(N = 605)
Age in years,
Mean (SD)
83.9
(7.1)
84.6
(6.9)
83.4
(7.2)
Age Group (N, %)

P-value
*
0.006
*

65-70

50

(3.7%)

38

(5.1%)

12

(2.0%)

0.001

71-75

146

(10.8%)

85

(11.3%)

61

(10.1%)

0.053

76-80

214

(15.8%)

119

(15.9%)

95

(15.7%)

0.060

81-85

334

(24.7%)

187

(25.0%)

147

(24.3%)

0.049

610

(45.1%)

320

(42.7%)

290

(47.9%)

0.007

*
*
>85 years
Gender (N, %)

*
Male
Female
Ethnicity (N, %)

692

(51.1%)

381

(50.9%)

311

(51.4%)

0.043

662

(48.9%)

368

(49.1%)

294

(48.6%)

1,281

(94.6%)

702

(93.7%)

579

(95.7%)

0.027

36

(2.7%)

22

(2.9%)

14

(2.3%)

0.106

*
Caucasian
African
American

*
Other
Region (N, %)

37

(2.7%)

25

(3.3%)

12

(2.0%)

0.043

Northeast

218

(16.1%)

111

(14.8%)

107

(17.7%)

<.0001

South

545

(40.3%)

315

(42.1%)

230

(38.0%)

<.0001

*
*
*
Midwest

356

(26.3%)

167

(22.3%)

189

(31.2%)

0.014
*

West

234

(17.3%)

155

(20.7%)

79

(13.1%)

Other

1

(0.1%)

1

(0.1%)

-

(0.0%)
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0.021

Table 3.2 (cont.) Characteristics of patients in the non-Hospice Cohort and
Hospice Cohort
Institutional
Non-hospice
Demographic
All Patients
hospice cohort
cohort patients
and clinical
patients
characteristics
(N = 1,354)
(N = 749)
(N = 605)
CCI (Mean,
SD)
3.3
(2.2)
3.1
(2.2)
3.5
(2.1)
CCI category

P-value
*
0.0002
*

0

138

(10.2%)

92

(12.3%)

46

(7.6%)

0.001
*

1

190

(14.0%)

123

(16.4%)

67

(11.1%)

0.001

2

197

(14.5%)

112

(15.0%)

85

(14.0%)

0.056

3

233

(17.2%)

116

(15.5%)

117

(19.3%)

0.010

4+
596
Comorbidities of interest

(44.0%)

306

(40.9%)

290

(47.9%)

0.002

*
*

*
AZ

238

(17.6%)

121

(16.2%)

117

(19.3%)

0.018
*

Dementia

1,088

(80.4%)

582

(77.7%)

506

(83.6%)

0.001
*

Pneumonia

390

(28.8%)

186

(24.8%)

204

(33.7%)

<.0001

Stroke

751

(55.5%)

395

(52.7%)

356

(58.8%)

0.004

*
*
CHF
553
(40.8%) 281 (37.5%)
272 (45.0%) 0.001
1
Demographics and health insurance plans were measured on or during the 6-mon pre-index
period. Comorbidities were measured during the baseline period, defined as the 6 month
period prior to the index date.
2
Chi-squared tests were used for comparisons of categorical variables (Fisher's Exact tests
were used for outcomes with small cell counts). Wilcoxon rank-sum tests were used for
comparisons of continuous variables.
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1
2

Corresponds to all-cause healthcare costs
Wilcoxon rank sum test was used for the comparison of unadjusted costs

*
*
*
*
*
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Table 3.3. Comparison of 3-Mon EOL Direct Healthcare Costs Between the Cohorts
Unadjusted cost, mean (SD)
Institutional
Non-hospice
hospice cohort
All
cohortpatients
patients
Direct Healthcare
P1
Costs
N = 1,354
N = 749
N = 605
value2
All-cause Costs
Total costs
$20,041 ($17,557) $18,530 ($16,457) $21,912 ($18,675)
<.0001
Inpatient costs
$9,686 ($16,013) $8,191 ($15,143) $11,537 ($16,858)
<.0001
Outpatient costs
$2,704 ($3,195)
$2,270 ($3,019)
$3,242 ($3,324)
<.0001
Pharmacy costs
$822 ($1,958)
$798 ($2,072)
$852 ($1,807)
0.0029
Palliative care
$6,828 ($4,926)
$7,270 ($4,955)
$6,281 ($4,839)
0.0002
costs

Table 3.4. Comparison of 9-Mon EOL Direct Healthcare Costs Between the cohorts
Unadjusted cost, mean (SD)

1
2

Non-hospice
cohort patients

N = 1,354

N = 749

N = 605

$50,116
$18,760
$6,037
$2,809

($33,616) $47,316 ($32,095) $53,581 ($35,128)
($26,253) $16,810 ($25,219) $21,174 ($27,307)
($5,813)
$5,383 ($5,918)
$6,847 ($5,579)
($5,491)
$2,802 ($5,744)
$2,817 ($5,166)

$13,506 ($12,394) $15,105 ($12,902) $11,526 ($11,439)

Corresponds to all-cause healthcare costs
Wilcoxon rank sum test was used for the comparison of unadjusted costs

Pvalue2
0.0001
<.0001
<.0001
0.0497

*
*
*
*

<.0001 *
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Direct Healthcare
Costs1
All-cause Costs
Total costs
Inpatient costs
Outpatient costs
Pharmacy costs
Palliative care
costs

All

Institutional
hospice cohort
patients

Table 3.5. Pairwise correlations between EOL care choice and instrumental
variables
EOL Choice
IV 1
IV 2
IV 3
(HHA)
EOL Choice
1.000
(HHA)
IV 1
0.012
1.000
r (p value)
(0.663)
IV 2

0.092

0.102

r (p value)

(0.001)

(0.0002)

IV 3

-0.068

0.129

-0.023

r (p value)

(0.012)

(<.0001)

(0.407)
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1.000

1.000

Table 3.6. First stage regression demonstrating whether instrumental
variables predict variance in the independent variable - Test of
individual significance
Characteristic
Parameter Estimate T-Value
Age
-0.005
-2.39
Female (Ref: Male)
0.003
-0.11
Region
S
0.06
1.63
MW
-0.04
-0.94
W
0.12
2.54
NE (Ref)
Race
African American
0.08
0.97
Other
0.10
1.22
Non-Hispanic White (Ref)
CCI Category
CCI Category: 1
CCI Category: 2
CCI Category: 3
CCI Category: 4
CCI Category: 0 (Ref)
Comorbidities
Alzheimer's Disease
Dementia
Pneumonia
Stroke
Congestive Heart Failure
Stage
Stage Moderate
Stage Advanced
Stage Unknown
Stage Mild (Ref)
IV 1
IV 3

P-value

0.017 *
0.912
0.103
0.349
0.011 *

0.334
0.221

-0.01
-0.07
-0.13
-0.08

-0.18
-1.17
-2.30
-1.50

0.854
0.242
0.021 *
0.133

-0.04
-0.06
-0.09
-0.03
-0.01
0.03
-0.05
0.00

-1.00
-1.60
-2.83
-0.88
-0.42
.
1.03
-0.67
0.07

0.316
0.110
0.005 *
0.380
0.672
.
0.305
0.500
0.946

0.03
-0.14

0.25
-1.76

0.806
0.079

*P-value < 0.05
Abbreviations: CI, Confidence Interval.
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Table 3.7. Hausman Test for Endogeneity
Variable
Estimate
t Value
EOL Choice: HHA
Age
Female (Ref: Male)
Region
S
MW
W
NE (Ref)
Race
African American
Other
Non-Hispanic White (Ref)
CCI Category
CCI Category: 1
CCI Category: 2
CCI Category: 3
CCI Category: 4
CCI Category: 0 (Ref)
Comorbidities
Alzheimer's Disease
Dementia
Pneumonia
Stroke
Congestive Heart Failure
Stage
Stage Moderate
Stage Advanced
Stage Unknown
Stage Mild (Ref)
Residual

p value

-1.800
-0.023
-0.050

-2.57
0.0104 *
-5.52 <.0001 *
-1.47
0.141

0.089
-0.211
0.226

1.4
-3.31
2.18

0.1608
0.0009 *
0.0295 *

0.441
0.232

3.66
1.89

0.0003 *
0.0586

-0.028
0.006
-0.075
0.216

-0.41
0.07
-0.67
2.49

0.6837
0.946
0.5001
0.0129 *

-0.118
-0.078
-0.026
0.100
0.142

-2.31
-1.31
-0.36
2.37
3.53

0.0209 *
0.1895
0.7177
0.0179 *
0.0004 *

0.094
-0.151
-0.046

1.98
-1.47
-1.15

0.048 *
0.1426
0.2509

1.733

2.47

0.0137 *
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Table 3.8. OLS model and 2SLS models Assessing the Relationship Between EOL Care Type and
Allcause Healthcare Costs During the 3 Mon EOL Period
Characteristic
EOL Choice: HHA
Age
Female (Ref: Male)
Region
S
MW
W
NE (Ref)
Race
African American
Other
Non-Hispanic White (Ref)

OLS Regression
Parameter Estimate
T-Value
P-value
-0.10
-2.46
0.014
*
-0.02
-5.93
<.0001 *
-0.10
-2.32
0.02
*

-0.09
-0.14
-0.02

-1.49
-2.14
-0.35

0.138
0.032
0.728

0.36
0.05

2.81
0.41

0.005
0.684

0.84
2.47
2.38
5.5

0.402
0.014
0.017
<.0001

-1.3
-1.03
3.08
2
4.27

0.194
0.301
0.002
0.045
<.0001

-0.99
-1.41
-0.93

0.323
0.159
0.351

CCI Category
CCI Category: 1
0.07
CCI Category: 2
0.21
CCI Category: 3
0.20
CCI Category: 4
0.45
CCI Category: 0 (Ref)
Comorbidities
Alzheimer's Disease
Dementia
-0.07
Pneumonia
-0.06
Stroke
0.14
Congestive Heart Failure
0.09
Stage
0.21
Stage Moderate
Stage Advanced
-0.05
Stage Unknown
-0.17
Stage Mild (Ref)
-0.05
* P-value < 0.05
Abbreviations: CI, Confidence Interval.
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2SLS Regression
Parameter Estimate
T-Value
P-value

-0.04
-0.02
-0.10

-0.1
-5.07
-2.34

0.921
<.0001
0.019

-0.09
-0.14
-0.03

-1.47
-2.02
-0.4

0.141
0.043
0.692

0.35
0.05

2.69
0.35

0.007
0.73

*
*
*

0.07
0.22
0.21
0.46

0.85
2.45
2.21
5.28

0.397
0.014
0.027
<.0001

*
*
*

*
*
*

-0.07
-0.05
0.15
0.09
0.21

-1.23
-0.9
2.69
2.01
4.3

0.217
0.369
0.007
0.044
<.0001

*
*
*

-0.05
-0.17
-0.05

-1.01
-1.38
-0.94

0.311
0.169
0.348

*

*

*
*

*

*

Table 3.9. OLS model and 2SLS model assessing the relationship between EOL Care Type
and Allcause Healthcare Costs During the 9 Mon EOL Period
Characteristic
EOL Choice: HHA
Age
Female (Ref: Male)
Region
S
MW
W
NE (Ref)
Race
African American
Other
Non-Hispanic White (Ref)

OLS Regression
Parameter Estimate
T-Value P-value
-0.07
-2.09 0.036 *
-0.01
-6
<.0001 *
-0.06
-1.73 0.085

2SLS Regression
Parameter Estimate
T-Value P-value

0.24
-0.01
-0.06

0.79 0.431
-4.56 <.0001 *
-1.73 0.084
-0.56 0.573
-1.88 0.06
-0.36 0.722

-0.01
-0.12
0.01

-0.24
-2.31
0.23

0.809
0.021 *
0.819

-0.03
-0.10
-0.02

0.29
0.07

2.77
0.64

0.006 *
0.52

0.26
0.04

2.37 0.018 *
0.33 0.739

-0.32
1.63
2.01
5.33

0.75
0.103
0.045 *
<.0001 *

-0.02
0.13
0.18
0.38

-0.3
1.8
2.22
5.25

0.767
0.071
0.027 *
<.0001 *

-1.28
0.54
3.25
3.91
4.12

0.199
0.592
0.001 *
<.0001 *
<.0001 *

-0.05
0.04
0.15
0.15
0.17

-1
0.87
3.22
3.95
4.1

0.32
0.386
0.001 *
<.0001 *
<.0001 *

0.87
-0.68
-1.09

0.383
0.495
0.275

0.03
-0.05
-0.04

CCI Category
CCI Category: 1
-0.02
CCI Category: 2
0.11
CCI Category: 3
0.14
CCI Category: 4
0.35
CCI Category: 0 (Ref)
Comorbidities
Alzheimer's Disease
-0.06
Dementia
0.02
Pneumonia
0.12
Stroke
0.15
Congestive Heart Failure
0.16
Stage
Stage Moderate
0.04
Stage Advanced
-0.07
Stage Unknown
-0.04
Stage Mild (Ref)
* P-value < 0.05
Abbreviations: CI, Confidence Interval.
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0.59 0.553
-0.51 0.61
-1.06 0.29
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Figure 3.1: Patient selection

Medicare patients who died between January 1, 2014 to December 31, 2016 will be
identified and date of death is will be considered as index date (N = 330,703)

Patients with at least two claims with a ICD-9 diagnosis code of 332.0 or ICD-10
diagnosis code G20 in the one-year period prior to index date (N = 13,415)

Patients who were at least 65 years as of January 1, 2014 who were continuously
enrolled in Medicare Parts A, B & D throughout the study period with no enrollment
in managed care plans, ESRD (N = 3,241)

Patients without any claim for cancer during the study period (N = 2,358)

Patients whose index date is between Apr 1, 2015 and December 31, 2016 (N = 2,226)

Patients whose used institutional or home-based palliative care during their end of life
period (N = 1,354)

Patients in non-hospice cohort (N =
605)

Patients in hospice cohort (N = 749)
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CHAPTER 5
Dissertation Summary and Future Research
Summary
Our study used Joinpoint regression to model all-cause healthcare costs prior to death. We
found that there is a significant change in the trend of all-cause costs in PD patients at months 3
and 9 prior to death indicating possible shift in the focus on patient’s care to palliative care. Using
results from Joinpoint regression and clinical judgement we determined the EOL period in PD
patients to be the 9-month period prior to death. While previous studies defined EOL period
arbitrarily or based on clinical judgement, our study used a data-driven approach which can be
used on a consistent basis to identify EOL phase.
Results from our study also indicate that direct healthcare costs during EOL period in PD
patients were significantly higher when compared to non-PD patients of similar demographics and
comorbidity burden. EOL costs in PD patients were driven by hospitalization costs and palliative
care costs where as EOL costs in non-PD cohort were driven by hospitalizations costs and
outpatient visit costs. Our study results also highlighted racial and geographic variation in EOL
costs in PD patients.
We assessed EOL costs among patients who used hospice services in EOL period and
patients who used non-hospice services. While previous studies found that patients with noncancer conditions and patients in general are more likely to use hospice care during EOL period,
our study found that the use of non-hospice EOL care is higher in PD patients when compared to
102

hospice based EOL care. We also assessed the relationship between place at death and EOL costs
using two approaches. In the first approach, results from OLS regression indicated that all-cause
costs in the non-hospice cohort were significantly lower than hospice cohort. However, due to the
presence of several unobserved confounders we used an instrumental variable approach to assess
the relationship between place at death and EOL costs. Results from IV model suggested that EOL
costs were higher in non-hospice cohort when compared to hospice cohort but the results did not
reach statistical significance.

Future Directions
Our study assessed the duration of EOL period in PD patients using a data-driven approach.
Future studies can use longer follow-up periods to identify phases of care during early stages of
PD so that phase-based costing models can be built to estimate life time costs of PD. Future studies
can assess EOL costs among PD patients who died before attaining age 65. Also, our current study
excluded patients who had cancer anytime during the study period. Further studies are required to
assess the incremental burden in PD patients with comorbid cancer. Last, our study assessed
association between place at death and EOL costs. Future studies can examine the association
between type of EOL care (hospice, home health etc.) and EOL costs so that novel EOL care
programs can be designed to reduce costs and improve patient’s EOL care experience.
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